

SCIRUS	<input type="text"/>	Search	Pop-up Blocker OFF	Highlight
--------	----------------------	--------	--------------------	-----------

About Us

Newsroom

Advisory Board

Submit Web Site

Help

Contact Us

Basic Search[Advanced Search](#) [Search Preferences](#)

Search

☒ Journal sources
 ☒ Preferred Web sources
 ☒ Other Web sources
 ☐ Exact phrase

Searched for:: :All of the words:author:cordingley AND (AIDS)

Found:: :10 total | [9 journal results](#) | [1 preferred web results](#) | [0 other web results](#)Sort by:: :relevance | [date](#)[Save checked results](#)[Email checked results](#)[Export checked results](#)

- ☐ 1. [Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir](#)

Doyon, L. / Tremblay, S. / Bourgon, L. / Wardrop, E. / Cordingley, M.G., *Antiviral Research*, Oct 2005

...Construction of recombinant HIV-1 The proviral DNA used to produce WT HIV-1 was plasmid 2.12, an HIV-1 encoding pNL4.3 plasmid (NIH AIDS Research and Reference Reagent Program) (Adachi et al., 1986), modified to contain a unique Bst1107I site at codon 125 of the...

Published journal article available from [SCIENCE @ DIRECT](#)

[view all 6 results from ScienceDirect](#)
[similar results](#)

- ☐ 2. [A novel model of HPV infection in meshed human foreskin grafts.](#)

Jianmin Duan / Josie De Marte / William Paris / Diana Roopchand / Tamara L Fleet / Jo-Anne Clarke / Siu-Hong Yeong / (...) / Michael G Cordingley, *Antiviral Res*, Dec 2004

...grafting to NIH-nu-bg-xid mice under halothane anesthesia. Cutaneous xenografts were dressed with antibiotics and protective band-aids for 3 weeks. In the paralleled experiment using the same viral stock containing both HPV6 and 11, and matched grafts, no visible...

MEDLINE/PubMed Citation on **PubMed**

[view all 2 results from MEDLINE/PubMed](#)
[similar results](#)

- ☐ 3. [A novel model of HPV infection in meshed human foreskin grafts](#)

Duan, J. / Marte, J.D. / Paris, W. / Roopchand, D. / Fleet, T.L. / Clarke, J.-A. / Yeong, S.-H. / (...) / Cordingley, M.G., *Antiviral Research*, Dec 2004

...grafting to NIH-nu-bg-xid mice under halothane anesthesia. Cutaneous xenografts were dressed with antibiotics and protective band-aids for 3 weeks. In the paralleled experiment using the same viral stock containing both HPV6 and 11, and matched grafts, no visible...

Published journal article available from [SCIENCE @ DIRECT](#)

[view all 6 results from ScienceDirect](#)





 Re
US
foi
cyt
pai
Or
AI
F

 HIV
Op!
Wai
regi
onc

 Hel
Eve
Chil
We

 Hel
Be
Inv
End

[similar results](#)

- ☐ 4. [HPMPC therapy of MCMV-induced retinal disease in the SCID mouse measured by electroretinography, a non-invasive...](#)
Garneau, M. / Bolger, G.T. / Bousquet, C. / Kibler, P. / Tremblay, F. / Cordingley, M.G., *Antiviral Research*, Aug 2003
 ...up to 40% of patients with acquired immunodeficiency syndrome (**AIDS**) were at risk to develop progressive retinal destruction leading...mice (Duan et al., 1994), while retrovirally induced murine **AIDS** (MAIDS) led to a higher incidence of necrotizing retinopathy...
Published journal article available from  **view all 6 results from ScienceDirect**
[similar results](#)
- ☐ 5. [USE OF A COMBINATION CONTAINING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR \(NNRTI\) WITH AN INHIBITOR OF CYTOCHROME...](#)
CORDINGLEY, Michael, Graham / BOEHRINGER INGELHEIM INTERNATIONAL GMBH, PATENT COOPERATION TREATY APPLICATION, Jul 2004
 ...HIV-1) which results in acquired immunodeficiency syndrome (**AIDS**) and related diseases. For this indication, the compound of the...and low dose ritonavir an attractive drug 10 combination for **AIDS** therapy. Those skilled in the art would know how to formulate...
Full text available at patent office. For more in-depth searching go to  **LexisNexis**
[similar results](#)
- ☐ 6. [Acute murine cytomegalovirus infection: a model for determining antiviral activity against CMV induced hepatitis](#)
Bolger, G. / Lapeyre, N. / Rheume, M. / Kibler, P. / Bousquet, C. / Garneau, M. / Cordingley, M., *Antiviral Research*, Dec 1999
 ...transplant, organ transplant followed by immunosuppressive therapy or **AIDS** (Betts, 1997). Mild CMV infection and rarely, severe CMV infection...hepatitis and acalculous cholecystitis have also been noted in **AIDS** patients (Drew, 1988 Pollard, 1988 Betts, 1997), while rare...
Published journal article available from  **view all 6 results from ScienceDirect**
[similar results](#)
- ☐ 7. [Experiences from the Structure Determination of Human Cytomegalovirus Protease](#)
Tong, L. / Qian, C. / Davidson, W. / Massariol, M.-J. / Bonneau, P.R. / Cordingley, M.G. / Lagacé, L., *Acta Crystallographica Section D: Biological Crystallography*, Nov 1997
 ...infections are clinically asymptomatic (Fields & Knipe, 1990). However, in immunosuppressed and immunocompromised individuals (**AIDS** patients and organ-transplant recipients), HCMV infections can cause severe health problems and even death (Fields & Knipe, 1990...
Published journal article available from  **similar results**
- ☐ 8. [A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease.](#)
L Tong / C Qian / M J Massariol / P R Bonneau / M G Cordingley / L Lagacé, *Nature*, Sep 1996
 ...population in the United States and can cause morbidity and mortality in immunosuppressed individuals (organ-transplant recipients and **AIDS** patients) and congenitally infected newborns. hCMV protease is essential for the production of mature infectious virions, as...

MEDLINE/PubMed Citation on



[view all 2 results from MEDLINE/PubMed](#)
[similar results](#)

- ☐ 9. [Dose and Treatment Duration-Dependence of Ganciclovir Against Murine Cytomegalovirus Infection in Severe Combined...](#)

Duan, J. / Paris, W. / Kibler, P. / Bousquet, C. / Liuzzi, M. / Cordingley, M.G.,
Antiviral Research, Apr 1997

...mutabon in tlte UL97 gene produt-t in a HCMV isolate from an **AIDS** pabenL F. Baldanti', A. Sarasini', L simoncini', M. Zavanoni...mone frequently detected in the clinical senings. A patient wtib **AIDS** and HCMV retinitis was submined to virological follow-up and...

Published journal article available from  **SCIENCE @ DIRECT**

[view all 6 results from ScienceDirect](#)
[similar results](#)


- ☐ 10. [Lethal Hepatitis During Acute HCMV Infection: Analysis and Treatment With Ganciclovir and HPMPC.](#)

Bolger, G. / Lapeyre, N. / Garneau, M. / Rheume, M. / Kibler, P. / Bousquet, C. / Cordingley, M.G.,
Antiviral Research, Apr 1997

...mutabon in tlte UL97 gene produt-t in a HCMV isolate from an **AIDS** pabenL F. Baldanti', A. Sarasini', L simoncini', M. Zavanoni...mone frequently detected in the clinical senings. A patient wtib **AIDS** and HCMV retinitis was submined to virological follow-up and...

Published journal article available from  **SCIENCE @ DIRECT**

[view all 6 results from ScienceDirect](#)
[similar results](#)



[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by FAST © Elsevier 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptarpi1623

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 "Ask CAS" for self-help around the clock
 NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
 NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered
 NEWS 5 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records
 NEWS 6 MAY 11 KOREAPAT updates resume
 NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
 NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and
 USPATFULL/USPAT2
 NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS
 NEWS 10 JUN 02 The first reclassification of IPC codes now complete in
 INPADOC
 NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
 and display fields
 NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 13 JUL 11 CHEMSAFE reloaded and enhanced
 NEWS 14 JUL 14 FSTA enhanced with Japanese patents
 NEWS 15 JUL 19 Coverage of Research Disclosure reinstated in DWPI

 NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
 MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8
 NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:12:26 ON 27 JUL 2006

=> FIL HCAPLUS

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FILE 'HCAPLUS' ENTERED AT 13:13:11 ON 27 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Jul 2006 VOL 145 ISS 5
FILE LAST UPDATED: 26 Jul 2006 (20060726/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> E "380378-81-4"/BI,RN 25
E1      1      380378-80-3/BI
E2      1      380378-80-3P/BI
E3      4 --> 380378-81-4/BI
E4      0      380378-81-4/RN
E5      1      380378-81-4D/BI
E6      2      380378-81-4P/BI
E7      1      380378-82-5/BI
E8      1      380378-82-5P/BI
E9      1      380378-83-6/BI
E10     1      380378-83-6P/BI
E11     2      380378-84-7/BI
E12     1      380378-84-7P/BI
E13     1      380378-85-8/BI
E14     1      380378-85-8P/BI
E15     1      380378-86-9/BI
E16     1      380378-86-9P/BI
E17     1      380378-87-0/BI
E18     1      380378-87-0P/BI
E19     1      380378-88-1/BI
E20     1      380378-88-1P/BI
E21     1      380378-89-2/BI
E22     1      380378-89-2P/BI
E23     4      380378-90-5/BI
E24     4      380378-90-5P/BI
E25     4      380378-91-6/BI
```


```
=> S E3
L1      4 380378-81-4/BI
```

```
=> DIS L1 1 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.74 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y
```

```
L1 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:445778 HCAPLUS
DOCUMENT NUMBER: 144:468213
TITLE: Process for preparation of diazepam N-oxide
```

derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors
 INVENTOR(S): Meyer, Oliver; Heddesheimer, Ingo; Zerban, Georg
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
 SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006048425	A1	20060511	WO 2005-EP55706	20051102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 2006100200 A1 20060511 US 2005-264281 20051101 PRIORITY APPLN. INFO.: EP 2004-26241 A 20041105 OTHER SOURCE(S): MARPAT 144:468213 GRAPHIC IMAGE:				



ABSTRACT:

The invention provides a process for preparing N-oxides of diazepine derivs. I [wherein R1 = Me, Et, cyclopropyl, Pr, iso-Pr, or cyclobutyl; R2 = H, F, Cl, alkyl, cycloalkyl, or CF3; R3 = H or Me, R4 = H, Me, or Et; Q = 1-oxido-4-quinolinyl or 1-oxido-5-quinolinyl] or pharmaceutically acceptable salts thereof, comprising oxidation of the corresponding diazepine derivs. under phase-transfer conditions. For example, I (R1 = Et; R2 and R3 = H; R4 = Me; Q = 4-quinolinyl) was treated with OXONE in CH2Cl2/water in the presence of tetrabutylammonium hydrogensulfate and acetone to give I (R1 = Et; R2 and R3 = H; R4 = Me; Q = 1-oxido-4-quinolinyl) with 99.3% purity. The title compds. are effective inhibitors of HIV reverse transcriptase (no data).

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L1 2- IALL

YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):Y
 THE ESTIMATED COST FOR THIS REQUEST IS 9.21 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1078236 HCAPLUS

DOCUMENT NUMBER: 143:353310

ENTRY DATE: Entered STN: 07 Oct 2005

TITLE: Crystalline forms of 5, 11-dihydro-11-ethyl-5-methyl-8-{2-[(1-oxido-4-quinolinyl)oxy]ethyl}-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepin-6-one and methods for preparation

INVENTOR(S): Busacca, Carl A.; Cerretà, Michael; Varsolona, Richard; Smoliga, John; Lorenz, Jon; Vitous, Jana
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany
SOURCE: U.S. Pat. Appl. Publ., 12 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

INT. PATENT CLASSIF.:

MAIN: A61K031-551

SECONDARY: C07D487-14

US PATENT CLASSIF.: 514220000; 540495000

CLASSIFICATION: 63-5 (Pharmaceuticals)

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005222134	A1	20051006	US 2005-83401	20050318
WO 2005097796	A2	20051020	WO 2005-US9655	20050323
WO 2005097796	A3	20060105		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-559354P P 20040402

PATENT CLASSIFICATION CODES:

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2005222134	ICM	A61K031-551
	ICS	C07D487-14
	INCL	514220000; 540495000
	IPCI	A61K0031-551 [ICM,7]; C07D0487-14 [ICS,7]; C07D0487-00 [ICS,7,C*]
	IPCR	A61K0031-551 [I,A]; A61K0031-551 [I,C*]; C07D0487-00 [I,C*]; C07D0487-14 [I,A]
	NCL	514/220.000
	ECLA	C07D471/14+245B+221B+221B
WO 2005097796	IPCI	C07D0471-14 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61K0031-551 [ICS,7]; A61P0031-18 [ICS,7]; A61P0031-00 [ICS,7,C*]
	IPCR	A61K0031-551 [I,A]; A61K0031-551 [I,C*]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]

ABSTRACT:

The present invention comprises the discovery of a dihydrate crystalline form of 5,11-dihydro-11-ethyl-5-methyl-8-{2-[(1-oxido-4-quinolinyl)oxy]ethyl}

-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, which is thermodynamically or kinetically favored at temps. and humidity's that are most likely to be encountered upon storage of drug substance or drug product and thus pharmaceutically preferred to the trihydrate that is provided by the prior art. The invention also comprises methods for making this dihydrate crystalline form. The invention further discovers that under proper conditions several anhydrous polymorphs of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one may be formed. One of these, which is designated as anhydrous Form III (AF III), has demonstrated phase stability at some tested ambient conditions, which indicates that it is pharmaceutically acceptable, and biol. testing has shown that it leads to higher plasma levels than are attainable using other crystalline forms of the drug. Thus, the invention further includes anhydrous Form III of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one and methods for its manufacture

SUPPL. TERM: cryst form anhyd diazepin dihydrate prepn
 INDEX TERM: Anti-AIDS agents
 Powder x-ray diffractometry
 (crystalline forms of 5,
 11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one and methods for preparation)
 INDEX TERM: Human immunodeficiency virus 1
 (reverse transcriptase inhibitor, treatment of; crystalline forms of 5, 11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one and methods for preparation)
 INDEX TERM: 380378-81-4 865887-44-1
 ROLE: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (crystalline forms of 5,
 11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one and methods for preparation)

L1 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:531365 HCAPLUS
 DOCUMENT NUMBER: 141:65063
 ENTRY DATE: Entered STN: 02 Jul 2004
 TITLE: Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) with an inhibitor of cytochrome p450 for the treatment of HIV-1 infection
 INVENTOR(S): Cordingley, Michael Graham
 PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
 SOURCE: PCT Int. Appl., 23 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 INT. PATENT CLASSIF.:
 MAIN: A61K031-55
 SECONDARY: A61K031-00; A61K031-427; A61P031-18
 CLASSIFICATION: 1-5 (Pharmacology)
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054586	A1	20040701	WO 2003-EP14224	20031215
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,			

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2510143	AA	20040701	CA 2003-2510143	20031215
AU 2003296647	A1	20040709	AU 2003-296647	20031215
US 2004152625	A1	20040805	US 2003-736301	20031215
EP 1575595	A1	20050921	EP 2003-813119	20031215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017095	A	20051025	BR 2003-17095	20031215
CN 1726041	A	20060125	CN 2003-80106301	20031215
JP 2006511538	T2	20060406	JP 2004-560402	20031215
NO 2005003455	A	20050810	NO 2005-3455	20050715

PRIORITY APPLN. INFO.:

US 2002-433690P	P	20021216
WO 2003-EP14224	W	20031215

PATENT CLASSIFICATION CODES:

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004054586	ICM	A61K031-55
	ICS	A61K031-00; A61K031-427; A61P031-18
	IPCI	A61K0031-55 [ICM,7]; A61K0031-00 [ICS,7]; A61K0031-427 [ICS,7]; A61P0031-18 [ICS,7]; A61P0031-00 [ICS,7,C*]
	IPCR	A61K0031-352 [I,C*]; A61K0031-353 [I,A]; A61K0031-427 [I,A]; A61K0031-427 [I,C*]; A61K0031-55 [I,A]; A61K0031-55 [I,C*]; A61K0031-551 [I,A]; A61K0031-551 [I,C*]; A61K0031-554 [I,A]; A61K0031-554 [I,C*]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0038-12 [I,C*]; A61K0038-13 [I,A]
	ECLA	A61K031/353+M; A61K031/427+M; A61K031/55+M; A61K031/551+M; A61K031/554+M; A61K031/7048+M; A61K035/78+M; A61K038/13+M
CA 2510143	IPCI	A61K0031-55 [ICM,7]; A61K0031-00 [ICS,7]; A61P0031-18 [ICS,7]; A61P0031-00 [ICS,7,C*]; A61K0031-427 [ICS,7]
	IPCR	A61K0031-352 [I,C*]; A61K0031-353 [I,A]; A61K0031-427 [I,A]; A61K0031-427 [I,C*]; A61K0031-55 [I,A]; A61K0031-55 [I,C*]; A61K0031-551 [I,A]; A61K0031-551 [I,C*]; A61K0031-554 [I,A]; A61K0031-554 [I,C*]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0038-12 [I,C*]; A61K0038-13 [I,A]
	ECLA	A61K031/353+M; A61K031/427+M; A61K031/55+M; A61K031/551+M; A61K031/554+M; A61K031/7048+M; A61K035/78+M; A61K038/13+M
AU 2003296647	IPCI	A61K0031-55 [ICM,7]; A61K0031-00 [ICS,7]; A61K0031-427 [ICS,7]; A61P0031-18 [ICS,7]; A61P0031-00 [ICS,7,C*]
	IPCR	A61K0031-352 [I,C*]; A61K0031-353 [I,A]; A61K0031-427 [I,A]; A61K0031-427 [I,C*]; A61K0031-55 [I,A]; A61K0031-55 [I,C*]; A61K0031-551 [I,A]; A61K0031-551 [I,C*]; A61K0031-554 [I,A]; A61K0031-554 [I,C*]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0038-12 [I,C*]; A61K0038-13 [I,A]
US 2004152625	IPCI	A61K0038-13 [ICM,7]; A61K0038-12 [ICM,7,C*]; A61K0031-7048 [ICS,7]; A61K0031-7042 [ICS,7,C*]; A61K0031-551 [ICS,7]; A61K0031-554 [ICS,7]; A61K0031-353 [ICS,7]; A61K0031-352 [ICS,7,C*]
	IPCR	A61K0031-352 [I,C*]; A61K0031-353 [I,A]; A61K0031-427 [I,A]; A61K0031-427 [I,C*]; A61K0031-55 [I,A]; A61K0031-55 [I,C*]; A61K0031-551 [I,A]; A61K0031-551 [I,C*]; A61K0031-554 [I,A]; A61K0031-554 [I,C*]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0038-12 [I,C*]; A61K0038-13 [I,A]

[I,C*]; A61K0031-554 [I,A]; A61K0031-554 [I,C*];
A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0038-12
[I,C*]; A61K0038-13 [I,A]

NCL 514/011.000

ECLA A61K031/353+M; A61K031/427+M; A61K031/55+M;
A61K031/551+M; A61K031/554+M; A61K031/7048+M;
A61K035/78+M; A61K038/13+M

EP 1575595 IPCI A61K0031-55 [ICM,7]; A61K0031-00 [ICS,7]; A61K0031-427
[ICS,7]; A61P0031-18 [ICS,7]; A61P0031-00 [ICS,7,C*]
IPCR A61K0031-352 [I,C*]; A61K0031-353 [I,A]; A61K0031-427
[I,A]; A61K0031-427 [I,C*]; A61K0031-55 [I,A];
A61K0031-55 [I,C*]; A61K0031-551 [I,A]; A61K0031-551
[I,C*]; A61K0031-554 [I,A]; A61K0031-554 [I,C*];
A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0038-12
[I,C*]; A61K0038-13 [I,A]

ECLA A61K031/353+M; A61K031/427+M; A61K031/55+M;
A61K031/551+M; A61K031/554+M; A61K031/7048+M;
A61K035/78+M; A61K038/13+M

BR 2003017095 IPCI A61K0031-55 [ICM,7]; A61K0031-00 [ICS,7]; A61K0031-437
[ICS,7]; A61K0031-4353 [ICS,7,C*]; A61P0031-18 [ICS,7];
A61P0031-00 [ICS,7,C*]
IPCR A61K0031-352 [I,C*]; A61K0031-353 [I,A]; A61K0031-427
[I,A]; A61K0031-427 [I,C*]; A61K0031-55 [I,A];
A61K0031-55 [I,C*]; A61K0031-551 [I,A]; A61K0031-551
[I,C*]; A61K0031-554 [I,A]; A61K0031-554 [I,C*];
A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0038-12
[I,C*]; A61K0038-13 [I,A]

ECLA A61K031/353+M; A61K031/427+M; A61K031/55+M;
A61K031/551+M; A61K031/554+M; A61K031/7048+M;
A61K035/78+M; A61K038/13+M

CN 1726041 IPCI A61K0031-55 [I,A]; A61K0031-00 [I,A]; A61K0031-427
[I,A]; A61P0031-18 [I,A]; A61P0031-00 [I,C*]
ECLA A61K031/353+M; A61K031/427+M; A61K031/55+M;
A61K031/551+M; A61K031/554+M; A61K031/7048+M;
A61K035/78+M; A61K038/13+M

JP 2006511538 IPCI A61K0031-551 [I,A]; A61K0045-00 [I,A]; A61K0031-427
[I,A]; A61P0031-18 [I,A]; A61P0031-00 [I,C*];
A61P0043-00 [I,A]

FTERM 4C084/AA19; 4C084/MA17; 4C084/MA35; 4C084/MA37;
4C084/MA52; 4C084/MA55; 4C084/MA59; 4C084/MA63;
4C084/MA66; 4C084/NA05; 4C084/NA14; 4C084/ZB331;
4C084/ZB332; 4C084/ZC202; 4C084/ZC551; 4C084/ZC552;
4C086/AA01; 4C086/AA02; 4C086/BC82; 4C086/CB11;
4C086/MA02; 4C086/MA04; 4C086/NA05; 4C086/NA14;
4C086/ZB33; 4C086/ZC20; 4C086/ZC55

NO 2005003455 IPCI A61K0031-55 [ICM,7]; A61K0031-00 [ICS,7]; A61K0031-427
[ICS,7]; A61P0031-18 [ICS,7]; A61P0031-00 [ICS,7,C*]
ECLA A61K031/353+M; A61K031/427+M; A61K031/55+M;
A61K031/551+M; A61K031/554+M; A61K031/7048+M;
A61K035/78+M; A61K038/13+M

ABSTRACT:

An improved method for using a NNRTI in the treatment of HIV-1 infection comprises administering to a human in need of treatment for HIV-1 infection a therapeutically effective amount of the NNRTI, or a pharmaceutically acceptable salt thereof, and an amount of an inhibitor of cytochrome P 450 that is sufficient to elevate, enhance, or extend plasma concns. of said NNRTI.

SUPPL. TERM: nonnucléoside reverse transcriptase inhibitor cytochrome
P450 inhibitor combination HIV1

INDEX TERM: AIDS (disease)
Anti-AIDS agents
Antiviral agents

Drug delivery systems
 Drug metabolism
 Grapefruit juice
 Human
 Human immunodeficiency virus
 Human immunodeficiency virus 1
 Pharmacokinetics
 (non-nucleoside reverse transcriptase inhibitor
 combination with cytochrome P 450 inhibitor for treatment
 of HIV-1 infection)
 INDEX TERM: Drug interactions
 (pharmacokinetic; non-nucleoside reverse transcriptase
 inhibitor combination with cytochrome P 450 inhibitor for
 treatment of HIV-1 infection)
 INDEX TERM: Infection
 (viral; non-nucleoside reverse transcriptase inhibitor
 combination with cytochrome P 450 inhibitor for treatment
 of HIV-1 infection)
 INDEX TERM: 9035-51-2, Cytochrome P 450, biological studies
 329322-82-9, Cytochrome P 450 3A
 ROLE: BSU (Biological study, unclassified); BIOL (Biological
 study)
 (non-nucleoside reverse transcriptase inhibitor
 combination with cytochrome P 450 inhibitor for treatment
 of HIV-1 infection)
 INDEX TERM: 380378-81-4
 ROLE: PAC (Pharmacological activity); PKT
 (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological
 study); USES (Uses)
 (non-nucleoside reverse transcriptase inhibitor
 combination with cytochrome P 450 inhibitor for treatment
 of HIV-1 infection)
 INDEX TERM: 114-07-8, Erythromycin 1406-18-4, Vitamin E 7380-40-7,
 Bergamottin 42399-41-7, Diltiazem 65277-42-1,
 Ketoconazole 79217-60-0, Cyclosporin 81103-11-9,
 Clarithromycin 83366-66-9, Nefazodone 84625-61-6,
 Itraconazole 116644-53-2, Mibefradil 145414-76-2
 150378-17-9, Indinavir 155213-67-5, Ritonavir
 159989-64-7, Nelfinavir 161814-49-9, Amprenavir
 198904-31-3, Atazanavir 380378-81-4D, mixts. with
 grapefruit juice 710282-28-3 710282-29-4 710282-30-7
 710282-31-8 710282-32-9 710282-33-0 710282-34-1
 710282-35-2 710282-36-3 710282-37-4 710282-38-5
 710282-39-6 710282-40-9 710282-41-0 710282-42-1
 710282-43-2
 ROLE: PAC (Pharmacological activity); THU (Therapeutic use);
 BIOL (Biological study); USES (Uses)
 (non-nucleoside reverse transcriptase inhibitor
 combination with cytochrome P 450 inhibitor for treatment
 of HIV-1 infection)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD.
 REFERENCE(S): (1) Barry, D; WO 9844913 A 1998 HCAPLUS
 (2) Boehringer Ingelheim Ca Ltd; WO 0196338 A 2001 HCAPLUS
 (3) Kaltenbach, R; US 6391919 B1 2002 HCAPLUS
 (4) Malaty, L; DRUG SAFETY 1999, V20(2), P147 HCAPLUS

L1 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:923799 HCAPLUS

DOCUMENT NUMBER: 136:37632

ENTRY DATE: Entered STN: 21 Dec 2001

TITLE: Preparation of non-nucleoside reverse transcriptase



inhibitors
 INVENTOR(S): Simoneau, Bruno
 PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
 SOURCE: PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 INT. PATENT CLASSIF.:
 MAIN: C07D471-14
 SECONDARY: A61K031-55; C07D471-14; C07D243-00; C07D221-00;
 C07D221-00
 CLASSIFICATION: 28-21 (Heterocyclic Compounds (More Than One Hetero
 Atom))
 Section cross-reference(s): 1, 63
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096338	A1	20011220	WO 2001-CA890	20010614
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2001002377	A	20020219	BR 2001-2377	20010612
US 2002028807	A1	20020307	US 2001-879447	20010612
US 6420359	B2	20020716		
CA 2411766	AA	20011220	CA 2001-2411766	20010614
CA 2411766	C	20060523		
EP 1294720	A1	20030326	EP 2001-949124	20010614
EP 1294720	B1	20060405		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004502787	T2	20040129	JP 2002-510480	20010614
EE 200200690	A	20040615	EE 2002-690	20010614
NZ 523549	A	20040827	NZ 2001-523549	20010614
AT 322492	E	20060415	AT 2001-949124	20010614
EP 1655300	A1	20060510	EP 2006-100695	20010614
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR			
ZA 2002009807	A	20031016	ZA 2002-9807	20021203
BG 107348	A	20040630	BG 2002-107348	20021203
NO 2002005844	A	20021205	NO 2002-5844	20021205
HK 1057558	A1	20050408	HK 2004-100468	20040121
PRIORITY APPLN. INFO.:			US 2000-212329P	P 20000616
			US 2000-256638P	P 20001218
			EP 2001-949124	A3 20010614
			WO 2001-CA890	W 20010614

PATENT CLASSIFICATION CODES:

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001096338	ICM	C07D471-14
	ICS	A61K031-55; C07D471-14; C07D243-00; C07D221-00; C07D221-00
	IPCI	C07D0471-14 [ICM,7]; A61K0031-55 [ICS,7]; C07D0471-14 [ICS,7]; C07D0471-00 [ICS,7,C*]; C07D0243-00 [ICS,7]; C07D0221-00 [ICS,7]

	IPCR	C07D0471-00 [I,C*]; C07D0471-14 [I,A]
	ECLA	C07D471/14+243B+221B+221B; C07D471/14+243+221+221
BR 2001002377	IPCI	C07D0471-14 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61P0031-18 [ICS,7]; A61P0031-00 [ICS,7,C*]
	IPCR	C07D0471-00 [I,C*]; C07D0471-14 [I,A]
	ECLA	C07D471/14+243B+221B+221B; C07D471/14+243+221+221
US 2002028807	IPCI	A61K0031-551 [ICM,7]; C07D0487-14 [ICS,7]; C07D0487-00 [ICS,7,C*]
	IPCR	C07D0471-00 [I,C*]; C07D0471-14 [I,A]
	NCL	514/220.000
	ECLA	C07D471/14+243B+221B+221B
CA 2411766	IPCI	A61K0031-55 [I,A]; C07D0221-00 [I,A]; C07D0243-00 [I,A]; C07D0471-14 [I,A]; C07D0471-00 [I,C*]
	IPCR	C07D0471-00 [I,C*]; C07D0471-14 [I,A]
	ECLA	C07D471/14+243B+221B+221B; C07D471/14+243+221+221
EP 1294720	IPCI	C07D0471-00 [I,C]; A61K0031-55 [I,C]; C07D0221-00 [N,C]; C07D0243-00 [N,C]; C07D0471-14 [I,A]; A61K0031-55 [I,A]; C07D0221-00 [N,A]; C07D0243-00 [N,A]
	IPCR	C07D0471-00 [I,C*]; C07D0471-14 [I,A]
	ECLA	C07D471/14+243B+221B+221B; C07D471/14+243+221+221
JP 2004502787	IPCI	C07D0471-14 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61K0031-551 [ICS,7]; A61P0031-18 [ICS,7]; A61P0031-00 [ICS,7,C*]; A61P0043-00 [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-14 [I,A]
	FTERM	4C065/AA04; 4C065/BB15; 4C065/CC05; 4C065/DD04; 4C065/EE03; 4C065/HH02; 4C065/JJ02; 4C065/KK04; 4C065/KK09; 4C065/LL04; 4C065/PP19; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/CB11; 4C086/MA04; 4C086/MA52; 4C086/MA55; 4C086/NA14; 4C086/ZB33; 4C086/ZC20; 4C086/ZC55
EE 200200690	IPCI	A61K0031-55 [ICM,7]; C07D0471-14 [ICS,7]; C07D0471-00 [ICS,7,C*]
	IPCR	C07D0471-00 [I,C*]; C07D0471-14 [I,A]
	ECLA	C07D471/14+243B+221B+221B; C07D471/14+243+221+221
NZ 523549	IPCI	C07D0471-14 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61K0031-55 [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-14 [I,A]
	ECLA	C07D471/14+243B+221B+221B; C07D471/14+243+221+221
AT 322492	IPCI	C07D0471-14 [ICS,7]; C07D0471-00 [ICS,7,C*]; A61K0031-55 [ICS,7]; C07D0221-00 [ICS,7]; C07D0243-00 [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-14 [I,A]
	ECLA	C07D471/14+243B+221B+221B; C07D471/14+243+221+221
EP 1655300	IPCI	C07D0471-14 [I,A]; A61K0031-55 [I,A]; C07D0471-14 [N,A]; C07D0471-00 [N,C*]; C07D0243-00 [N,A]; C07D0221-00 [N,A]
ZA 2002009807	IPCI	A61K [ICM,7]; C07D [ICS,7]
BG 107348	IPCI	C07D0471-14 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61K0031-55 [ICS,7]; C07D0243-00 [ICS,7]; C07D0221-00 [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-14 [I,A]
	ECLA	C07D471/14+243B+221B+221B; C07D471/14+243+221+221
NO 2002005844	IPCI	C07D0471-14 [ICM,7]; C07D0471-00 [ICM,7,C*]
	ECLA	C07D471/14+243B+221B+221B; C07D471/14+243+221+221
HK 1057558	IPCI	C07D [ICM,7]; A61K [ICS,7]; A61P [ICS,7]
	IPCR	C07D0471-00 [I,C*]; C07D0471-14 [I,A]
	ECLA	C07D471/14+243B+221B+221B; C07D471/14+243+221+221
OTHER SOURCE(S):		MARPAT 136:37632
GRAPHIC IMAGE:		



ABSTRACT:

Compds. of formula I [R2 = H, F, Cl, (C1-4) alkyl, (C3-4) cycloalkyl, CF3; R4 = H, Me; R5 = H, Me, Et; R4 and R5 are not both Me, and if R4 is Me then R5 cannot be Et; R11 = Et, cyclopropyl, Pr, iso-Pr, isobutyl; Q = 4- or 5-quinolinyl or their 1-oxides] are prepared as inhibitors of HIV reverse transcriptase, wild-type and several mutant strains. Thus, II was prepared in several steps from 2-chloro-3-nitropyridine, ethylamine, 5-bromo-2-chloro-3-pyridinecarbonyl chloride and 4-hydroxyquinoline. II was shown to inhibit wild-type and mutant strains of reverse transcriptase in assays.

SUPPL. TERM: dipyridodiazepinone deriv prepn reverse transcriptase inhibitor; HIV replication inhibitor dipyridodiazepinone deriv prepn

INDEX TERM: Anti-AIDS agents
(preparation of dipyridodiazepinone derivs. as inhibitors of HIV replication)

INDEX TERM: 9068-38-6, Reverse transcriptase
ROLE: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of dipyridodiazepinone derivs. as reverse transcriptase inhibitors)

INDEX TERM: 380378-62-1P 380378-63-2P 380378-64-3P 380378-65-4P
380378-66-5P 380378-68-7P 380378-69-8P 380378-70-1P
380378-71-2P 380378-72-3P 380378-73-4P 380378-74-5P
380378-75-6P 380378-76-7P 380378-77-8P 380378-78-9P
380378-79-0P 380378-80-3P 380378-81-4P
380378-82-5P 380378-83-6P 380378-84-7P 380378-85-8P
380378-86-9P 380378-87-0P 380378-88-1P 380378-89-2P
380378-97-2P 380379-14-6P 380379-15-7P 380379-17-9P
380379-39-5P
ROLE: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dipyridodiazepinone derivs. as reverse transcriptase inhibitors)

INDEX TERM: 578-67-6, 5-Hydroxyquinoline 611-36-9, 4-Hydroxyquinoline
765-30-0, Cyclopropylamine 1513-65-1, 2,6-Difluoropyridine
2393-23-9, 4-Methoxybenzylamine 5470-18-8,
2-Chloro-3-nitropyridine 16013-85-7, 2,6-Dichloro-3-nitropyridine
17129-06-5, 4-Ethoxy-1,1,1-trifluoro-3-buten-2-one 24850-33-7, Allyltributyltin 26163-29-1

39745-40-9 49609-84-9, 2-Chloronicotiny1 chloride
 78686-86-9 129432-25-3 380379-38-4

ROLE: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of dipyridodiazepinone derivs. as reverse
 transcriptase inhibitors)

INDEX TERM: 26820-65-5P 32282-06-7P 33742-69-7P 58602-02-1P
 117519-07-0P 134698-42-3P 142266-58-8P 162109-00-4P
 189391-94-4P 189393-15-5P 189393-17-7P 189393-18-8P
 211750-50-4P 380378-90-5P 380378-91-6P 380378-92-7P
 380378-93-8P 380378-94-9P 380378-95-0P 380378-96-1P
 380378-98-3P 380378-99-4P 380379-00-0P 380379-01-1P
 380379-02-2P 380379-03-3P 380379-04-4P 380379-05-5P
 380379-06-6P 380379-07-7P 380379-08-8P 380379-09-9P
 380379-10-2P 380379-11-3P 380379-12-4P 380379-13-5P
 380379-16-8P 380379-18-0P 380379-19-1P 380379-20-4P
 380379-21-5P 380379-22-6P 380379-23-7P 380379-24-8P
 380379-25-9P 380379-26-0P 380379-27-1P 380379-28-2P
 380379-29-3P 380379-30-6P 380379-31-7P 380379-32-8P
 380379-33-9P 380379-34-0P 380379-35-1P 380379-36-2P
 380379-37-3P

ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP
 (Preparation); RACT (Reactant or reagent)
 (preparation of dipyridodiazepinone derivs. as reverse
 transcriptase inhibitors)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD.

REFERENCE(S): (1) Cywin, C; J MED CHEM 1998, V41(16), P2972 HCAPLUS

=> S E5

L2 1 380378-81-4D/BI

=> DIS L2 1 TI

L2 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN

TI Use of a combination containing a non-nucleoside reverse transcriptase
 inhibitor (NNRTI) with an inhibitor of cytochrome p450 for the treatment
 of HIV-1 infection

=> S E6

L3 2 380378-81-4P/BI

=> DIS L3 1- TI

YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):Y

L3 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

TI Process for preparation of diazepam N-oxide derivatives as non-nucleoside
 HIV-1 reverse transcriptase inhibitors

L3 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of non-nucleoside reverse transcriptase inhibitors

Basic Search

[Advanced Search](#) [Search Preferences](#)

"reverse transcriptase inhibitors" AND ("combination therapy" AND ritonavir

Search

☒ Journal sources ☒ Preferred Web sources ☒ Other Web sources ☐ Exact phrase

Searched for:: :All of the words:"reverse transcriptase inhibitors" AND ("combination therapy" AND ritonavir

Found:: :**96 total** | **21 journal results** | **7 preferred web results** | **68 other web results**

Sort by:: :**relevance** | **date**

Save checked results

Email checked results

Export checked results

- ☐ 1. [Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and...](#)

Rezk, N.L. / Tidwell, R.R. / Kashuba, A.D.M., *Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences*, Jul 2002

...quantification of the **non-nucleoside reverse transcriptase inhibitors** nevirapine...**non-nucleoside reverse transcriptase inhibitors** (nevirapine...**non-nucleoside reverse transcriptase inhibitors** proved to...activity of, the **cytochrome P450** enzyme...consequences of **combination therapy** with NNRTIs...

Published journal article available from  **SCIENCE @ DIRECT**

[view all 21 results from ScienceDirect](#)
[similar results](#)

- ☐ 2. [Metabolic complications associated with antiretroviral therapy](#)
Jain, R.G. / Furfine, E.S. / Pedneault, L. / White, A.J. / Lenhard, J.M., *Antiviral Research*, Sep 2001

...NRTIs and **non-nucleoside reverse transcriptase...nucleoside reverse transcriptase inhibitors** (NRTIs), **non-nucleoside reverse transcriptase inhibitors** (NNRTIs...Nucleoside **reverse transcriptase inhibitors** inhibitors...Norvir(R)/Ritonavir (RTV) Viracept...

Published journal article available from  **SCIENCE @ DIRECT**

[view all 21 results from ScienceDirect](#)
[similar results](#)

- ☐ 3. [Antiretroviral therapy of HIV-1 Infection: established treatment strategies and new therapeutic options](#)

Kaufmann, G.R. / Cooper, D.A., *Current Opinion in Microbiology*, Oct 2000

...shown that **non-nucleoside reverse transcriptase inhibitors**, such as...regimens. Triple **combination therapy** that includes...analogue **reverse transcriptase inhibitors** (nRTIs...saquinavir/ritonavir and saquinavir...investigations. 6 **Non-nucleoside analogue reverse transcriptase inhibitors** An alternative...lamivudine **combination**

Refine your search using these key words found in the results:
[antiretroviral therapy](#)
[hiv-1 infection](#)
[hiv disease](#)
[hiv-infected patient](#)
[human immunodeficiency virus](#)
[human immunodeficiency virus type](#)
[protease inhibitors](#)
[zidovudine](#)

Or refine using:

All of the words

Refine

therapy. Adding nevirapine...

Published journal article available from  **SCIENCE @ DIRECT**

[view all 21 results from ScienceDirect](#)

[similar results](#)

- ☐ 4. [Effect of reduced-dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected...](#)

Stein, A.J. / Brothers, C.H. / Scott, T.R., *Clinical Therapeutics*, Mar 2001
...an inhibitor of the **cytochrome** P450 isoenzyme 3A4 (**CYP 3A4**),
ritonavir in low doses (eg...Both amprenavir and **ritonavir** are substrates
and...amprenavir 600 mg BID plus **ritonavir** 100 mg BID delivers...in the
absence of **non-nucleoside reverse transcriptase inhibitors**-is
appropriate when...Meta-analysis of triple **combination therapy** in
antiretroviral...

Published journal article available from  **SCIENCE @ DIRECT**

[view all 21 results from ScienceDirect](#)

[similar results](#)

- ☐ 5. [Targeting HIV: antiretroviral therapy and development of drug resistance](#)

Menendez-Arias, L., *Trends in Pharmacological Sciences*, Aug 2002
...V82A, I84V, L90M h **Ritonavir** L10I/R/V, K20M/R...virus type 1 NNRTIs,
non-nucleoside reverse transcriptase inhibitors PR, protease RT,
reverse...administration of low doses of **ritonavir**, which
significantly...elimination by the hepatic **cytochrome** P450 enzyme
system...coadministration with **ritonavir**. **Combination therapy** and
multidrug-resistant...

Published journal article available from  **SCIENCE @ DIRECT**

[view all 21 results from ScienceDirect](#)

[similar results](#)

- ☐ 6. [HIV disease treatment in the era of HAART](#)

Bonfanti, P. / Capetti, A. / Rizzardini, G., *Biomedicine & Pharmacotherapy*, Mar 1999

...PIs) or **non-nucleoside reverse transcriptase inhibitors**
(NNRTIs...trial on **combination therapy** in advanced...Metabolism
cytochrome P450 cyt...investigating **combination therapy** with
two...such as **non- nucleoside reverse transcriptase inhibitors**
(NNRTIs...

Published journal article available from  **SCIENCE @ DIRECT**

[view all 21 results from ScienceDirect](#)

[similar results](#)

- ☐ 7. [Development of resistance of human immunodeficiency virus \(HIV\) to anti-HIV agents: how to prevent the problem?](#)

De Clercq, E., *International Journal of Antimicrobial Agents*, Jun 1997
...saquinavir, **ritonavir**, indinavir...inhibitors: **Reverse transcriptase inhibitors** 1. Introduction...nucleoside **reverse transcriptase inhibitors**
(NRTIs: AZT...d4T, 3TC), **non-nucleoside reverse transcriptase**...Clercq E.
Non-nucleoside reverse transcriptase inhibitors (NNRTIs...of initial
combination therapy with zidovudine...

Published journal article available from  **SCIENCE @ DIRECT**

[view all 21 results from ScienceDirect](#)

[similar results](#)

- ☐ 8. [HCV chronic hepatitis in patients with HIV: clinical management issues](#)

Bruno, R. / Sacchi, P. / Puoti, M. / Soriano, V. / Filice, G., *The American Journal of Gastroenterology*, Jul 2002





...i.e. , **ritonavir**) Immune reconstitution...nucleoside **reverse**

transcriptase inhibitors, acting as...effect on the **cytochrome** p450 isoenzyme...receiving **ritonavir** was no higher...patients. Among **non-nucleoside reverse transcriptase inhibitors**, nevirapine...




Published journal article available from  **SCIENCE @ DIRECT**

[view all 21 results from ScienceDirect](#)

[similar results](#)

- ☐ 9. [British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals](#)
BHIVA Guidelines Co-ordinating Committee / Gazzard, B. / Moyle, G. / Weber, J. / Johnson, M. / Bingham, J. / Brettle, R. / (...) / Griffin, G., *The Lancet*, Apr 1997
...Protease inhibitors **Non-nucleoside reverse transcriptase inhibitors** Zidovudine (ZDV, AZT...Zalcitabine (ddC) **Ritonavir** Delavirdine* Didanosine...nucleoside analogues plus a **non-nucleoside** reverse transcriptase...inhibitors Saquinavir+ritonavir Two nucleoside analogues...patients already on **combination therapy**. For these patients...that in late disease **ritonavir** will improve outcome...
Published journal article available from  **SCIENCE @ DIRECT**
[view all 21 results from ScienceDirect](#)
[similar results](#)
- ☐ 10. [Antiretroviral drug toxicity - a challenge for the hepatologist?](#)
Spengler, U. / Lichterfeld, M. / Rockstroh, J.K., *Journal of Hepatology*, Feb 2002
...inhibitors (NRTI), **non-nucleoside reverse transcriptase inhibitors** (NNRTI) and...ng/ml) c **Cytochrome** P450 isoenzymes...Nucleoside **reverse transcriptase inhibitors** Zidovudine...**Non-nucleoside reverse transcriptase inhibitors** Delavirdine...CYP2C9, CYP2D6 **Ritonavir** Norvir (R...
Published journal article available from  **SCIENCE @ DIRECT**
[view all 21 results from ScienceDirect](#)
[similar results](#)
- ☐ 11. [Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism,...](#)
Warren Beach, J., *Clinical Therapeutics*, Jan 1998
...inhibitors (saquinavir, **ritonavir**, indinavir, and...drugs. Key words: **reverse transcriptase inhibitors**, protease inhibitors...Jersey). 14 the **CYP-450** system by the...metabolism.,In addition, **ritonavir**, nelfinavir, delavirdine...saquinavir is limited to **combination therapy** because of the development...protease gene. 17,88 **Ritonavir** In contrast to saquinavir...In addition, the **CYP-2D6** isoform contributes...
Published journal article available from  **SCIENCE @ DIRECT**
[view all 21 results from ScienceDirect](#)
[similar results](#)
- ☐ 12. [Highly active antiretroviral therapy \(Haart\) for the treatment of infection with human immunodeficiency virus type 1](#)
Shafer, R.W. / Vuitton, D., *Biomedicine & Pharmacotherapy*, Mar 1999
...available HIV-I **non-nucleoside** RT inhibitors...Iâ€™™450 **CYP** 3A enzymes...common muta- **CYP** IA enzymes...enzymes P236L **Non-nucleoside** RT inhibitors (NNRTI) The **non-nucleoside reverse transcriptase inhibitors** (NNRTI) inhibit...
Published journal article available from  **SCIENCE @ DIRECT**
[view all 21 results from ScienceDirect](#)
[similar results](#)

- ☐ 13. Neuroscience research in AIDS
Rausch, D.M. / Stover, E.S., *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, Jan 2001
 The human immunodeficiency virus invades the central nervous system early after infection where it later gives rise to cognitive, motor, and behavioral manifestations in children and adults. Ranging from mild impairments to frank...
Published journal article available from [SCIENCE @ DIRECT](#)
[view all 21 results from ScienceDirect](#)
[similar results](#)
- ☐ 14. High-performance liquid chromatography of HIV protease inhibitors in human biological matrices
Aarnoutse, R.E. / Verweij-van Wissen, C.P.W.G.M. / Underberg, W.J.M. / Kleinnijenhuis, J. / Hekster, Y.A. / Burger, D.M., *Journal of Chromatography B: Biomedical Sciences and Applications*, Nov 2001
 ...nucleoside **reverse transcriptase inhibitors** (NRTIs) and **non-nucleoside reverse transcriptase inhibitors** (NNRTIs...nelfinavir, **ritonavir**, saquinavir...one of the **cytochrome P450** iso...Especially **ritonavir** is a potent...applied in **combination therapy**. However...
Published journal article available from [SCIENCE @ DIRECT](#)
[view all 21 results from ScienceDirect](#)
[similar results](#)
- ☐ 15. Human immunodeficiency virus type-1 protease inhibitors - therapeutic successes and failures, suppression and...
Swanstrom, R. / Erona, J., *Pharmacology and Therapeutics*, May 2000
 ...analogs. **Combination therapy** in which...nelfinavir NNRTI, **non-nucleoside** reverse transcriptase...transcriptase RTV, **ritonavir** SGC, soft...clinical use 150 **Ritonavir** 151 Indinavir...inhibitors in **combination therapy** 157 Protease...nucleoside analog **reverse transcriptase inhibitors** 157 The use...combined with **non-nucleoside reverse transcriptase inhibitors** 160 Salvage...
Published journal article available from [SCIENCE @ DIRECT](#)
[view all 21 results from ScienceDirect](#)
[similar results](#)
- ☐ 16. Pharmaceutical biotechnology
Current Opinion in Biotechnology, Dec 1997
 In addition, the bibliography contains every paper annotated by reviewers; these references were obtained from a variety of bibliographic databases and published between the beginning of the review period and the time of going to press.
Published journal article available from [SCIENCE @ DIRECT](#)
[view all 21 results from ScienceDirect](#)
[similar results](#)
- ☐ 17. Adverse effects of antiretroviral therapy
Carr, A. / Cooper, D.A., *The Lancet*, Oct 2000
 ...nucleotide-analogue HIV **reverse-transcriptase inhibitors** Organ Features...lamivudine, NNRTI=**non-nucleoside** reverse transcriptase...Mouth ulcers **Non-nucleoside** analogues...formulation) **Ritonavir** Perioral paraesthesiae...paraesthesiae All **Cytochrome P450** interaction...effective **combination therapy** Nat Med 5...effects of **reverse transcriptase inhibitors**:mitochondrial...
Published journal article available from [SCIENCE @ DIRECT](#)
[view all 21 results from ScienceDirect](#)
[similar results](#)

- ☐ **18. Antiretroviral Therapy in the 1990's: Recent Advances**
Gopalakrishnan, R., *Antimicrobics and Infectious Diseases Newsletter*, Jul. 1996
...superiority of **combination therapy** over monotherapy...approved for **combination therapy**. An attractive...agents are the **non-nucleoside reverse transcriptase**...in chronic **combination therapy** is yet to be...saquinavir, **ritonavir**, and indinavir...combination with **reverse transcriptase inhibitors**, it has resulted...
Published journal article available from 
[view all 21 results from ScienceDirect](#)
[similar results](#)
- ☐ **19. Influence of mitochondrial control of apoptosis on the pathogenesis, complications and treatment of HIV infection**
Phenix, B.N. / Badley, A.D., *Biochimie*, Feb 2002
...molecule (vpr52-96) causes release of **cytochrome c** and apoptosis-inducing factor (AIF...followed by mitochondrial release of **cytochrome c** and cleavage of caspases 9 and 3...activation of these enzymes leads to **cytochrome c** release from mitochondria into the...
Published journal article available from 
[view all 21 results from ScienceDirect](#)
[similar results](#)
- ☐ **20. Human immunodeficiency virus therapy and potential anesthetic interactions**
Hernandez Conte, A.T., *Seminars in Anesthesia, Perioperative Medicine and Pain*, Dec 1998
...institution of **combination therapy** with reverse...Nucleoside **reverse transcriptase inhibitors** Zidovudine...Nonnucleoside **reverse transcriptase inhibitors** Nevirapine...Pharmaceuticals) **Ritonavir** (Norvir...bination with **reverse transcriptase inhibitors**. The most...the hepatic **cytochrome P450** system...to AZT.22 **Ritonavir.e3 Ritonavir**...
Published journal article available from 
[view all 21 results from ScienceDirect](#)
[similar results](#)



Results Pages: [[<< Prev](#)] [1](#) [2](#) [[Next >>](#)]

[back to top](#)

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by **FAST** © Elsevier 2006

About Us

Newsroom

Advisory Board

Submit Web Site

Help

Contact Us

Basic Search

[Advanced Search](#) [Search Preferences](#)

"cyp 450" AND ritonavir and AIDS

Search

☒ Journal sources ☒ Preferred Web sources ☒ Other Web sources ☐ Exact phrase

Searched for:: :All of the words:"**cyp 450**" AND **ritonavir** AND **AIDS**

Found:: :**23 total** | **4 journal results** | **14 preferred web results** | **5 other web results**

Sort by:: :**relevance** | **date**

Save checked results

Email checked results

Export checked results

Or refine using:

All of the words

Refine

HIV/AIDS Treatment
Find What You Need
About An HIV/AIDS
Treatment

Sponsor

1. Tenofovir disoproxil fumarate: A nucleotide reverse transcriptase inhibitor for the treatment of HIV infection

Fung, H.B. / Stone, E.A. / Piacenti, F.J., *Clinical Therapeutics*, Oct 2002
...gained the attention of the HIV/**AIDS** community when Che-Chung Tsai...SIV), a primate model for **AIDS**. All macaques that received...meeting abstracts of major HIV/ **AIDS** conferences (1996-2002), using...substrates of the cytochrome P (**CYP**)-**450** enzymes.Z1 Although induction...amprenavir, indinavir, nelfinavir, **ritonavir**, and saquinavir) in MT-2 cells...

Published journal article available from **SCIENCE @ DIRECT**

[view all 4 results from ScienceDirect](#)

[similar results](#)

2. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism,...

Warren Beach, J., *Clinical Therapeutics*, Jan 1998
...for the treatment of **AIDS** (Figure 1). Zidovudine...Dermatologic Rash Bs **Ritonavir** CNS effects General weakness...metabolites are produced by the **CYP-450** 3A isozymes, but in vitro...New Jersey). 14 the **CYP-450** system by the 3A4 isoform...metabolism.,In addition, **ritonavir**, nelfinavir, delavirdine...

Published journal article available from **SCIENCE @ DIRECT**

[view all 4 results from ScienceDirect](#)

[similar results](#)

3. Amprenavir: A New Human Immunodeficiency Virus Type 1 Protease Inhibitor

Fung, H.B. / Kirschenbaum, H.L. / Hameed, R., *Clinical Therapeutics*, May 2000

...October 1996 (when most patients with **AIDS** were receiving a protease in- hlator...significantly higher in patients with **AIDS** than in healthy individuals (27 ,LLM vs...concentratlons reported in patients with **AIDS** (27 WM). Based on thermodynamic and kmetic...inhibitors: indinavir, saquinavir, nelfinavir, **ritonavir**, and amprenavir. At trough

concentrations...

Published journal article available from 

[view all 4 results from ScienceDirect](#)

[similar results](#)

☐ 4. [Full length article](#)

Viard, J.-P. / Rouzioux, C., *Annales de l'Institut Pasteur/Actualites*, Jul 2000

...saquinavir, Invirase R et Fortovase **ritonavir**, NorvirW indinavir, Crixivan R nelfinavir...dans les urines) ? urinaire 45 hpatique (**CYP-450**) 0,4 hpatique (CYP3A4) 0,65-1,2hpatique...t bien tabli que de petites doses de **ritonavir** augmentent l aire sous la courbe du saquinavir...patienst receiving HIV protease rnhibitors, **AIDS** 12 (1998) F51-F58. 99 Le sX d re is StAir...

Published journal article available from 

[view all 4 results from ScienceDirect](#)

[similar results](#)



[Downloads](#) | [Subscribe to News Updates](#) | [User Féedback](#) | [Advertising](#)
[Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

[Powered by FAST](#) © Elsevier 2006

About Us

Newsroom

Advisory Board

Submit Web Site

Help

Contact Us

Basic Search

[Advanced Search](#) [Search Preferences](#)

"cyp 450" AND ritonavir and AIDS

Search

☒ Journal sources ☒ Preferred Web sources ☒ Other Web sources ☐ Exact phrase

Searched for:: :All of the words:"cyp 450" AND ritonavir AND AIDS


Found:: :23 total | [4 journal results](#) | [14 preferred web results](#) | [5 other web results](#)

Sort by:: :relevance | [date](#)

Save checked results

Email checked results

Export checked results

- ☐ 1. [JOURNAL 7/02](#) [PDF-263K]
Aug 2002
...INTERNATIONAL ASSOCIATION OF PHYSICIANS IN **AIDS** CARE Headquarters Office Chicago, Illinois...INTERNATIONAL ASSOCIATION OF PHYSICIANS IN **AIDS** CARE Southern Africa Regional Office Johannesburg...International Association of Physicians in **AIDS** Care. All material published, including...
[more hits from](#) [<http://www.thebody.org/iapac/pdfs/jul02.pdf>]
[similar results](#)
- ☐ 2. [JOURNAL 7/02/YES](#) [PDF-144K]
Dec 2002
...Combination therapy with indinavir, **ritonavir**, and delavirdine and nucleoside reverse...transcriptase inhibitors in patients with HIV/**AIDS** who have failed multiple antiretroviral...efficacy of the combination of indinavir, **ritonavir**, delavirdine, and two NRTIs was examined...193-199 A randomized trial of nelfinavir, **ritonavir**, or delavirdine in combination with...
[<http://www.hawaii.edu/hivandaids/ARV%20Drug%20Monograp...>]
[similar results](#)
- ☐ 3. [Tenofovir disoproxil fumarate: A nucleotide reverse transcriptase inhibitor for the treatment of HIV infection](#)
Fung, H.B. / Stone, E.A. / Piacenti, F.J., Clinical Therapeutics, Oct 2002
...gained the attention of the HIV/**AIDS** community when Che-Chung Tsai...SIV), a primate model for **AIDS**. All macaques that received...meeting abstracts of major HIV/**AIDS** conferences (1996-2002), using...substrates of the cytochrome P (**CYP**)-450 enzymes.Z1 Although induction...amprenavir, indinavir, nelfinavir, **ritonavir**, and saquinavir) in MT-2 cells...
Published journal article available from 
[view all 4 results from ScienceDirect](#)
[similar results](#)
- ☐ 4. [Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism,...](#)
Warren Beach, J., Clinical Therapeutics, Jan 1998
...for the treatment of **AIDS** (Figure 1). Zidovudine...Dermatologic Rash Bs **Ritonavir**

Re
us
for
eth
nel
pro
sar
zid
Or
AI
F
HIV
Finc
Abc
Tre:

CNS effects General weakness...metabolites are produced by the **CYP-450** 3A isozymes, but in vitro...New Jersey). 14 the **CYP-450** system by the 3A4 isoform...metabolism.,In addition, **ritonavir**, nelfinavir, delavirdine...

Published journal article available from 

[view all 4 results from ScienceDirect](#)

[similar results](#)

☐ 5. [82454\\$\\$\\$P3](#) [PDF-818K]

Nov 2001

We com- pared patients' daily drug costs on two internal medicine wards and conducted a secondary analysis of data from a controlled study. A drug-prescribing sheet used for both prescribing and administration of drugs was used on ward A.

[<http://www.sdu.dk/health/Homepages/EACPT/eacpt5/PTO890...>]

[similar results](#)

☐ 6. [Amprenavir: A New Human Immunodeficiency Virus Type 1 Protease Inhibitor](#)

Fung, H.B. / Kirschenbaum, H.L. / Hameed, R., *Clinical Therapeutics*, May 2000

...October 1996 (when most patients with **AIDS** were receiving a protease inhibitor...significantly higher in patients with **AIDS** than in healthy individuals (27 ,LLM vs...concentrations reported in patients with **AIDS** (27 WM). Based on thermodynamic and kinetic...inhibitors: indinavir, saquinavir, nelfinavir, **ritonavir**, and amprenavir. At trough concentrations...

Published journal article available from 

[view all 4 results from ScienceDirect](#)

[similar results](#)

☐ 7. [SCHOOL OF PHARMACY](#) [PDF-12K]

May 2001

...agents in the treatment of HIV/**AIDS** may be found at the HIV/**AIDS** Treatment Information Service...Fortovase® or Invirase®), **ritonavir** (Norvir®), indinavir (Crixivan...shows similar results. The **AIDS** Clinical Trial Group (ACTG...metabolized by the cytochrome (**CYP**) 450 system. Efavirenz is an inducer...


[<http://www.spahs.umn.edu/DIS/pdf/sustiva.pdf>]

[similar results](#)

☐ 8. [INDIVIDUALIZATION OF THERAPY WITH ANTIBIOTIC AGENTS](#)

LEYLAND-JONES, Brian / MCGILL UNIVERSITY, PATENT COOPERATION TREATY APPLICATION, Nov 2002

The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with...

Full text available at patent office. For more in-depth searching go to  LexisNexis


[view all 14 results from Patent Offices](#)

[similar results](#)

☐ 9. [INDIVIDUALIZATION OF THERAPY WITH ALZHEIMER'S DISEASE AGENTS](#)

LEYLAND-JONES, Brian / MCGILL UNIVERSITY, PATENT COOPERATION TREATY APPLICATION, Dec 2002

The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with...

Full text available at patent office. For more in-depth searching go to  LexisNexis

[view all 14 results from Patent Offices](#)


[similar results](#)

☐ 10. [INDIVIDUALIZATION OF THERAPY WITH HYPERLIPIDEMIA AGENTS](#)

LEYLAND-JONES, Brian / MCGILL UNIVERSITY, PATENT COOPERATION TREATY APPLICATION, Nov 2002

The invention relates to the individualization of therapy on the basis of a phenotypic


profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[view all 14 results from Patent Offices](#)
[similar results](#)

☐ **11. INDIVIDUALIZATION OF THERAPY WITH ANALGESICS**

LEYLAND-JONES, Brian / MCGILL UNIVERSITY, PATENT COOPERATION TREATY APPLICATION, Nov 2002


The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[view all 14 results from Patent Offices](#)
[similar results](#)

☐ **12. INDIVIDUALIZATION OF THERAPY WITH ANTINEOPLASTIC AGENTS**

LEYLAND-JONES, Brian / MCGILL UNIVERSITY, PATENT COOPERATION TREATY APPLICATION, Nov 2002


The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[view all 14 results from Patent Offices](#)
[similar results](#)

☐ **13. INDIVIDUALIZATION OF THERAPY WITH ERECTILE DYSFUNCTION AGENTS**

LEYLAND-JONES, Brian / MCGILL UNIVERSITY, PATENT COOPERATION TREATY APPLICATION, Nov 2002


The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with ED...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[view all 14 results from Patent Offices](#)
[similar results](#)

☐ **14. INDIVIDUALIZATION OF THERAPY WITH GASTROESOPHAGEAL REFLUX DISEASE AGENTS**

LEYLAND-JONES, Brian / MCGILL UNIVERSITY, PATENT COOPERATION TREATY APPLICATION, Oct 2002

The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with GERD...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[view all 14 results from Patent Offices](#)
[similar results](#)

☐ **15. INDIVIDUALIZATION OF THERAPY WITH ANTIARRHYTHMICS**

LEYLAND-JONES, Brian / MCGILL UNIVERSITY, PATENT COOPERATION TREATY APPLICATION, Oct 2002


The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[view all 14 results from Patent Offices](#)
[similar results](#)

☐ **16. METABOLIC PHENOTYPING IN THERAPY WITH ANXIOLYTICS**

LEYLAND-JONES, Brian / MCGILL UNIVERSITY, PATENT COOPERATION TREATY APPLICATION, Sep 2002


The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[view all 14 results from Patent Offices](#)
[similar results](#)

☐ 17. INDIVIDUALIZATION OF THERAPY WITH ANTIPSYCHOTICS

LEYLAND-JONES, Brian / MCGILL UNIVERSITY, PATENT COOPERATION TREATY APPLICATION, Sep 2002


The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[view all 14 results from Patent Offices](#)
[similar results](#)

☐ 18. METABOLIC PHENOTYPING IN THERAPY WITH IMMUNOSUPPRESSANTS

LEYLAND-JONES, Brian / MCGILL UNIVERSITY, PATENT COOPERATION TREATY APPLICATION, Sep 2002


The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[view all 14 results from Patent Offices](#)
[similar results](#)

☐ 19. INDIVIDUALIZATION OF THERAPY WITH ANTIDEPRESSANTS

LEYLAND-JONES, Brian / MCGILL UNIVERSITY, PATENT COOPERATION TREATY APPLICATION, Sep 2002


The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[view all 14 results from Patent Offices](#)
[similar results](#)

☐ 20. USE OF METABOLIC PHENOTYPING IN INDIVIDUALIZED TREATMENT WITH AMONAFIDE

LEYLAND-JONES, Brian / MCGILL UNIVERSITY, PATENT COOPERATION TREATY APPLICATION, Sep 2002

The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with the drug,...

Full text available at patent office. For more in-depth searching go to  LexisNexis[®]
[view all 14 results from Patent Offices](#)
[similar results](#)



Results Pages: [[<< Prev](#)] 1 [2](#) [[Next >>](#)]

[back to top](#)

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by [FAST](#) © Elsevier 2006

About Us

Newsroom

Advisory Board

Submit Web Site

Help

Contact Us

Basic Search

[Advanced Search](#) [Search Preferences](#)

"cyp 450" and AIDS AND metabolism AND (keyword:ri

Search

☒ Journal sources ☒ Preferred Web sources ☒ Other Web sources ☐ Exact phrase

Searched for:: :All of the words:"**cyp 450**" AND **AIDS** AND **metabolism** AND (keyword:ritonavir)

Found:: :**2 total** | **0 journal results** | **0 preferred web results** | **2 other web results**

Sort by:: :**relevance** | date

Save checked results

Email checked results

Export checked results

☐ 1. [JOURNAL 7/02](#) [PDF-263K]

Aug 2002

...INTERNATIONAL ASSOCIATION OF PHYSICIANS IN **AIDS** CARE
Headquarters Office Chicago, Illinois...INTERNATIONAL ASSOCIATION OF
PHYSICIANS IN **AIDS** CARE Southern Africa Regional Office
Johannesburg...International Association of Physicians in **AIDS** Care. All
material published, including...
[<http://www.thebody.org/iapac/pdfs/jul02.pdf>]
[similar results](#)

☐ 2. [JOURNAL 7/02/YES](#) [PDF-144K]

Dec 2002

...Delavirdine inhibits the CYP3A4- mediated **metabolism** of protease
inhibitors and thereby increases...an effective inducer of delavirdine
metabolism: A steady state pharmacokinetic interaction...resulting in the
induction of its own **metabolism**. Efavirenz has an elimination half-life...
[<http://www.hawaii.edu/hivandaids/ARV%20Drug%20Monograp...>]
[similar results](#)

Did you mean?
["cyp 450" "acid
metabolism" \(keyv](#)

Or refine using:

All of the words

Refine

Metabolism, Stre:
Does stress affect yo
metabolism? See w
can help.

Rebuild Your Meta
Speed Up Your **Meta**
Burn Fat. Free Pills, :
Guarantee

Lose 9 lbs. every 1
Learn the 10 Idiot Pr
Weight Loss & Dietin

fast

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by **FAST** © Elsevier 2006

Basic Search

[Advanced Search](#) [Search Preferences](#)

"cyp 450" AND ritonavir and AIDS

Search

☒ Journal sources ☒ Preferred Web sources ☒ Other Web sources ☐ Exact phrase

Searched for:: :All of the words:"cyp 450" AND ritonavir AND AIDS

Found:: :123 total | [6 journal results](#) | [21 preferred web results](#) | [96 other web results](#)

Sort by:: :relevance | [date](#)

Save checked results

Email checked results

Export checked results

1. [Pharmacologic Enhancement in Protease Inhibitor-based HAART: The Role of Ritonavir](#) [132K]
Stephen L. Becker / Lorna Thornton, Sep 2004
...reason to justify their use. Adding **ritonavir**, however, is not without cost. Abnormalities...improvement rendered by the addition of **ritonavir**. Understanding the pharmacologic origins...malignancy, and a lowered incidence of any **AIDS**-defining diagnosis among patients with...enhancement of PI therapy (boosting) with **ritonavir**, itself an inhibitor of HIV protease...
[more hits from](#) [http://www.hivandhepatitis.com/recent/pibosted/020204_...]
[similar results](#)
2. [HIV & AIDS](#) [PPT-2MB]
Feb 2006
...Hyperbilirubinemia Lopinavir/**Ritonavir** (Kaletra®, LPV/RTV) 3 capsules...Recommended for use in pregnancy **Ritonavir** (Norvir®, RTV) The "Booster...BREAK http://www.unfpa.org/aids_clock/main.htm 58 Resistance...Efavirenz 100-250 Saquinavir 2100 **Ritonavir** 800 Nelfinavir 1000 Lopinavir...Protease Inhibitors and NNRTIs **CYP 450** 3A4 Inhibitors and inducers...
[http://pharmacy.umkc.edu/New/pharm/PharmacotherapyIII/...]
[similar results](#)
3. [JOURNAL 7/02](#) [PDF-263K]
Aug 2002
...INTERNATIONAL ASSOCIATION OF PHYSICIANS IN **AIDS** CARE Headquarters Office Chicago, Illinois...INTERNATIONAL ASSOCIATION OF PHYSICIANS IN **AIDS** CARE Southern Africa Regional Office Johannesburg...International Association of Physicians in **AIDS** Care. All material published, including...
[more hits from](#) [http://www.thebody.org/iapac/pdfs/jul02.pdf]
[similar results](#)
4. [Norvir, INN- Ritonavir](#) [PDF-84K]
Oct 2005
...procedure. However a new formulation of **ritonavir**, Norvir 100 mg soft capsules has...further developed. Active substance **Ritonavir** is a chiral molecule. The enantiomeric...starting materials. Two polymorphs of **ritonavir** referred to as Forms I


Re
US
foi
anl
anl
anl
dri
dri
hiv
hiv
hu
vir
me
ne
opi
p-c
ph
rev
inh
vir
zid
Or
Al
F
HIV
Finc
Abc
Tre

and II are...

[more hits from \[http://www.emea.eu.int/humandocs/PDFs/EPAR/Norvir/0527...\]](http://www.emea.eu.int/humandocs/PDFs/EPAR/Norvir/0527...)
[similar results](#)

- ☐ 5. [JOURNAL 7/02/YES \[PDF-144K\]](#)
 Dec 2002
 ...Combination therapy with indinavir, **ritonavir**, and delavirdine and nucleoside reverse...transcriptase inhibitors in patients with HIV/**AIDS** who have failed multiple antiretroviral...efficacy of the combination of indinavir, **ritonavir**, delavirdine, and two NRTIs was examined...193-199 A randomized trial of nelfinavir, **ritonavir**, or delavirdine in combination with...
[more hits from \[http://www.hawaii.edu/hivandaids/ARV%20Drug%20Monograp...\]](http://www.hawaii.edu/hivandaids/ARV%20Drug%20Monograp...)
[similar results](#)

- ☐ 6. [HIV Report November 1997 - Supplement \[62K\]](#)
 Dec 2005
 Johns Hopkins **AIDS** Service- Main Navigation 1997...Recommendation Symptomatic (**AIDS**, thrush, unexplained fever...ddI Nelfinavir d4T + ddI **Ritonavir** ZDV + ddC **Ritonavir** + Saquinavir ZDV + 3TC d4T...agents have opposite effects on **CYP 450** pathway and this must be considered...
[more hits from \[http://hopkins-aids.edu/publications/report/supplement...\]](http://hopkins-aids.edu/publications/report/supplement...)
[similar results](#)



- ☐ 7. [Depression in HIV-infected patients - Allopathic, complementary, and alternative treatments](#)
Fulk, L.J. / Kane, B.E. / Phillips, K.D. / Bopp, C.M. / Hand, G.A., Journal of Psychosomatic Research, Oct 2004
 ...a result of HIV/**AIDS**, and gender [7...of nefazodone and **ritonavir** (a protease transcriptase...example, not only does **ritonavir** exert effects on...have an effect on **CYP-450** isoenzyme-mediated...not interact with **CYP-450** system [27] . May...
Published journal article available from 
[view all 6 results from ScienceDirect](#)
[similar results](#)

- ☐ 8. [IAPAC \[103K\]](#)
 Feb 2006
 ...morbidity and mortality rates. Even before the **AIDS** pandemic, an estimated 50 percent of adults...HIV infection, accounting for a third of **AIDS**-related deaths worldwide. In addition...The Joint United Nations Programme on HIV/**AIDS** (UNAIDS) estimated that out of a global...
[\[http://www.iapac.org/home.asp?pid=77&toolid=2&itemid=9...\]](http://www.iapac.org/home.asp?pid=77&toolid=2&itemid=9...)
[similar results](#)

- ☐ 9. [Initiating Antiretroviral Therapy \[110K\]](#)
Erna M. Kojic / Charles C.J. Carpenter, May 2006
 ...as a PI (with low-dose **ritonavir**) with an NNRTI and one...concomitant use of low-dose **ritonavir**, which boosts plasma...drugs. **Ritonavir** inhibits **CYP 450** in both the gastrointestinal...enhancement is primarily due to **CYP 450** inhibition in the liver...
[more hits from \[http://hivinsite.ucsf.edu/InSite?page=kb-03-02-05\]](http://hivinsite.ucsf.edu/InSite?page=kb-03-02-05)
[similar results](#)

- ☐ 10. [DRUG - DRUG INTERACTIONS BETWEEN HAART MEDICATIONS USED \[PDF-47K\]](#)
 Aug 2005
 ...alcohol dependence) Inhibits some **CYP 450** enzymes May interact with ARVs6...generally required. 8. Saquinavir/**Ritonavir** **AIDS** Clinical Trials Group (ACTG) 401 evaluated the effects of saquinavir/**ritonavir** (400 mg/400 mg) on the pharmacokinetics...
[\[http://hivguidelines.org/public_html/sub-ddi/sub-ddi.p...\]](http://hivguidelines.org/public_html/sub-ddi/sub-ddi.p...)
[similar results](#)

- 11. [eMedicine - Incontinence, Urinary: Nonsurgical Therapies : Article by Jong M Choe, MD,](#)

- ☐ **FACS†** [180K]
Apr 2006
...neuropathy. Less common causes of overflow incontinence include **AIDS**, genital herpes affecting the perineal area, and neurosyphilis...neuropathy. Less common causes of overflow incontinence include **AIDS**, genital herpes affecting the perineal area, and neurosyphilis...
[more hits from \[http://www.emedicine.com/med/topic3085.htm\]](http://www.emedicine.com/med/topic3085.htm)
[similar results](#)
- ☐ **12. Microsoft Word - anticonvulsant-int.doc** [PDF-29K]
Jul 2005
...enzyme induction potential for **ritonavir** concentrations and/or phenobarbital...patient started in 3TC, ddI, **ritonavir** 600mg BID, and saquinavir...concentrations Topiramate **CYP 450** enzymes no major interaction...12 Potent Enzyme Inhibitors **Ritonavir** - Norvir® 13 Lopinavir/**Ritonavir**...
[<http://www.tthivclinic.com/pdf/anticonvulsant-int.pdf>]
[similar results](#)
- ☐ **13. PowerPoint Presentation** [PPT-7MB]
Mar 2006
...Urine In the HIV/**AIDS** patient the diagnosis...cytochrome P450 (**CYP-450**) enzymes which then...Cytochrome P450 (**CYP-450**). Rifampin (& ST. John's Wort) induce **CYP-450** reducing the concentration...NNRTIs. PIs NNRTIs **Ritonavir** Nevirapine Saquinavir...
[<http://medicine.nova.edu/academics/clinical/forms/HIV1...>]
[similar results](#)
- ☐ **14. NIDA - Interactions Between Drugs of Abuse and Pharmacotherapeutic Agents Used in the Treatment of AIDS and Drug Addiction** [45K]
May 2006
...their attachment with high affinity. **Ritonavir** is the most potent inhibitor of CYP3A4...with oxygen at the iron site of CYP. **Ritonavir** and nelfinavir, besides inhibiting CYP3A4...isozyme to induce their own metabolism. **Ritonavir** also inhibits CYP2D6. Indinavir, amprenavir...greatly complicate the link between HIV/**AIDS** and substance abuse. HIV PIs and NNRTIs...
[<http://www.drugabuse.gov/MeetSum/Interactions.html>]
[similar results](#)
- ☐ **15. Candida albicans endocarditis treatment with caspofungin in an HIV-infected patient-case report and review of literature**
Bacak, V. / Biocina, B. / Starcevic, B. / Gertler, S. / Begovac, J., Journal of Infection, Jul 2006
...Begovac a ? josip.begovac@zg.htnet.hr a Department of HIV/**AIDS**, University Hospital for Infectious Diseases, Mirogojska 8...Antiretroviral treatment with stavudine, lamivudine and lopinavir/**ritonavir** was started in April 2004. Discussion We present a case of...expected, as methadone is primarily metabolized by hepatic **CYP 450** enzymes, and caspofungin is not substantially metabolized...
Published journal article available from  **SCIENCE @ DIRECT**
[view all 6 results from ScienceDirect](#)
[similar results](#)
- ☐ **16. USE OF A COMBINATION CONTAINING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) WITH AN INHIBITOR OF CYTOCHROME...**
CORDINGLEY, Michael, Graham / BOEHRINGER INGELHEIM INTERNATIONAL GMBH, PATENT COOPERATION TREATY APPLICATION, Jul 2004
...administering either a single **CYP 450** inhibitor or more than one **CYP 450** inhibitor. The invention...acceptable salt, and the **CYP 450** inhibitor or inhibitors...Procedures by which **ritonavir** ((2S,3S,5S)-5-(N-(N...immunodeficiency syndrome (**AIDS**) and related diseases...
Full text available at patent office. For more in-depth searching go to  **LexisNexis®**

[view all 21 results from Patent Offices](#)
[similar results](#)

☐ **17. CLINICAL MANAGEMENT OF** [PDF-928K]

Aug 2004

...a collaborative effort of the Southeast **AIDS** Training and Education Center, Department...Infectious Disease Program the Midwest **AIDS** Training and Education Center at the University...Patricia Yeargin, RN, MN, MPH, CANP Southeast **AIDS** Training and Education Center, Emory University...

[<http://www.seatec.emory.edu/clinicalprotocols/clinical...>]

[similar results](#)

☐ **18. 03Sept_NL_12pg.qxd** [PDF-81K]

Sep 2003

...Number 5 The Johns Hopkins University **AIDS** Service September 2003 A bimonthly...other clinical trials suggesting that **ritonavir**-boosted PIs are more potent than unboosted...atazanavir (ATV, Reyataz) with lopinavir/**ritonavir** (LPV/r, Kaletra) were presented at...more impressive in BMS-045, in which **ritonavir**- boosted ATV (ATV/RTV 300/100 mg qd...Director, The Johns Hopkins University **AIDS** Service Richard E. Chaisson, M.D. Professor...

[more hits from](http://www.aegis.com/files/JHopkins/JH2003-09.pdf) [<http://www.aegis.com/files/JHopkins/JH2003-09.pdf>]

[similar results](#)

☐ **19. Psychotropic drug guide new.qxd (Page 1)** [PDF-25K]

Mar 2006

...in patients with advanced **AIDS**. It is best to start with...specific to this combination . **Ritonavir** is a moderately strong 2D6...Kaletra) Nelfinavir (Viracept) **Ritonavir** (Norvir) Saquinavir(Fortovase...in patients with advanced **AIDS**. In these patients, start...NNRTIs. Phenytoin: known to be **CYP 450** 3A4 enzyme inducer, may decrease...Carbamazepine levels increased by **ritonavir** (Kato). Phenytoin: Co-administration...

[<http://www.ucsf.edu/sfaetc/resources/CORREFMANUAL/docs...>]

[similar results](#)

☐ **20. HAART** [PDF-40K]

Jul 2005

...gestación 2.- Basado en IP Lopinavir/**ritonavir** (co-formulación) + (Lamivudina o Emtricitabina...Abacavir o Didanosina) o (Tenofovir + **ritonavir** 100mg/d) Fosamprenavir + (Lamivudina...Tenofovir o Didanosina) Fosamprenavir/**ritonavir** + (Lamivudina o Emtricitabina) + (Zidovudina...

[more hits from](http://www.upch.edu.pe/tropicales/telemedicinatarga/RE...) [<http://www.upch.edu.pe/tropicales/telemedicinatarga/RE...>]

[similar results](#)



Results Pages: [[<<](#) [Prev](#)] [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [[Next](#) [>>](#)]

[back to top](#)

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by **FAST** © Elsevier 2006

[About Us](#)
[Newsroom](#)
[Advisory Board](#)
[Submit Web Site](#)
[Help](#)
[Contact Us](#)
[Basic Search](#)
[Advanced Search](#) [Search Preferences](#)

☒ Journal sources ☒ Preferred Web sources ☒ Other Web sources ☐ Exact phrase

Searched for:: :All of the words:keyword:ritonavir AND ("combination therapy")

 Found:: :219 total | [99 journal results](#) | [5 preferred web results](#) | [115 other web results](#)

 Sort by:: :relevance | [date](#)

- ☐ 1. [AEGIS-05CROI: Ritonavir \(RIT\) pharmacokinetics \(PK\) during combination therapy with delavirdine \(DLV\).](#) [6K]
 Feb 1998
 ...Retroviruses and Opportunistic Infections Chicago, IL - February 1-5, 1998 Ritonavir (RIT) pharmacokinetics (PK) during **combination therapy** with delavirdine (DLV). Conf Retroviruses Opportunistic Infect 1998 Feb 1-5 5th:143 (abstract no. 343) Morse GD... [more hits from \[http://www.aegis.com/conferences/CROI/1998/343.html\]](#)
[similar results](#)

- ☐ 2. [Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.](#)
Ferdinand W N M Wit / Gerrit Jan Weverling / Jan Weel / Suzanne Jurriaans / Joep M A Lange, J Infect Dis, Jul 2002
 This retrospective cohort study investigated whether particular antiretroviral agents are associated with a higher risk for developing grade 4 liver enzyme elevations (LEEs) in patients with human immunodeficiency virus (HIV) type 1 infection who are...

MEDLINE/PubMed Citation on PubMed
[view all 65 results from MEDLINE/PubMed](#)
[similar results](#)

- ☐ 3. [Recurrent ingrown toenails secondary to indinavir/ritonavir combination therapy.](#)
C W James / K C McNelis / D M Cohen / S Szabo / A K Bincsik, Ann Pharmacother, Jul 2001
 ...indinavir/ritonavir (IDV/RTV) **combination therapy**. CASE SUMMARY: The median...elected to maintain IDV/RTV **combination therapy**. Two patients experienced...receiving ongoing IDV/RTV **combination therapy**. DISCUSSION: IGTV and paronychia...

MEDLINE/PubMed Citation on PubMed
[view all 65 results from MEDLINE/PubMed](#)
[similar results](#)

- ☐ 4. [COMBINATION THERAPY FOR THE TREATMENT OF AIDS](#)
VACCA, Joseph, P. / LIN, Jiunn, H. / YEH, Kuang, C. / CHODAKEWITZ, Jeffrey,

 Re
US
foi
ad
an
chi
col
did
hiv
hiv
ne
nu
nu
opi
res
go
ret
sta
tim
tra
Or
Al
F

 Key
The
terr

 Key
Unc

A. / DEUTSCH, Paul, J. / JU, William, D. / MERCK & / CO., INC., EUROPEAN PATENT, Oct 2000

...present invention provides **combination therapy** for the treatment of HIV...the invention to provide a **combination therapy** which lowers HIV viral levels...Zidovudine and Lamivudine. This **combination therapy** is a method to enhance the...

Full text available at patent office. For more in-depth searching go to LexisNexis

[view all 5 results from Patent Offices](#)

[similar results](#)

Nicl
Adv
Fin:
Adl
Dis:
pro:
larg

- ☐ 5. [Response to two consecutive protease inhibitor combination therapy regimens in a cohort of HIV-1-infected children.](#)

Gerardo C Palacios / Veronica L Palafox / Maria T Alvarez-Muñoz / Guillermo Vazquez / Guadalupe Miranda / Onofre Muñoz / Fortino Solorzano, *Scand J Infect Dis*, Feb 2002

The response to 2 consecutive protease inhibitor (P1) combination regimens was evaluated in a cohort of HIV-1-infected children. Twelve children, most of whom had been heavily treated, received a 3-drug treatment: saquinavir in hard gelatin capsules...

MEDLINE/PubMed Citation on PubMed

[view all 65 results from MEDLINE/PubMed](#)

[similar results](#)

- ☐ 6. [Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.](#)

Steven G Deeks / Jason D Barbour / Robert M Grant / Jeffrey N Martin, *AIDS*, Jan 2002

BACKGROUND: Sustained elevations in CD4 cell counts commonly occur despite incomplete viral suppression with protease inhibitor-based antiretroviral therapy.

OBJECTIVES: To determine the incidence and risk factors associated with return of CD4 cell...

MEDLINE/PubMed Citation on PubMed

[view all 65 results from MEDLINE/PubMed](#)

[similar results](#)

- ☐ 7. [An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection:...](#)

Initio Co-ordinating Committee, *Control Clin Trials*, Apr 2001

This article discusses the design of an ongoing open-label, randomized trial comparing three strategies of initial and subsequent HIV therapy in terms of long-term immunological and virological effect. The three treatment arms are (1) didanosine (ddI)...

MEDLINE/PubMed Citation on PubMed

[view all 65 results from MEDLINE/PubMed](#)

[similar results](#)

- ☐ 8. [Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected...](#)

J K Rockstroh / F Bergmann / W Wiesel / A Rieke / A Thiesen / G Fätkenheuer / M Oette / (...) / H Knechten, *AIDS*, Jun 2000

...lamivudine (38%) or stavudine/didanosine (13%) plus ritonavir 400 mg twice daily and indinavir 400 mg twice daily **combination therapy**. CD4 cell counts and HIV RNA were determined at weeks 0, 4, 8, 12, 16, 20, and 24. Statistical analysis was performed...

MEDLINE/PubMed Citation on PubMed

[view all 65 results from MEDLINE/PubMed](#)

[similar results](#)

- ☐ 9. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks.

C P Raines / C Flexner / E Sun / M Heath-Chiozzi / R H Lewis / C Fields / C Deetz / (...) / **J E Gallant**, *J Acquir Immune Defic Syndr*, Dec 2000

OBJECTIVE: To evaluate the safety, tolerability, and anti-HIV activity of ritonavir-nelfinavir (RTV-NFV). DESIGN: Single-site, open-label, nonrandomized, multiple-dose trial of RTV combined with two doses of NFV in protease inhibitor (PI)-naive,...

MEDLINE/PubMed Citation on PubMed

[view all 65 results from MEDLINE/PubMed](#)
[similar results](#)

- ☐ 10. Ritonavir combination therapy restores intestinal function in children with advanced HIV disease.

R B Canani / M I Spagnuolo / P Cirillo / A Guarino, *J Acquir Immune Defic Syndr*, Aug 1999

...and after treatment with **combination therapy** that includes ritonavir. To test the hypothesis that **combination therapy** improves intestinal function...months after institution of **combination therapy**. Mean results of each of...

MEDLINE/PubMed Citation on PubMed

[view all 65 results from MEDLINE/PubMed](#)
[similar results](#)

- ☐ 11. Clinical efficacy of protease inhibitor based antiretroviral combination therapy--a prospective cohort study.

B Salzberger / J Rockstroh / U Wieland / C Franzen / A Schwenk / A Jütte / P Hegener / (...) / **G Fätkenheuer**, *Eur J Med Res*, Nov 1999

...suppression) and PI used (Saquinavir vs. Indinavir or Ritonavir, RR 2.7).

CONCLUSIONS: Virological failure of PI based **combination therapy** is common and associated with advanced HIV-infection. Clinical failure is associated with advanced HIV-infection...

MEDLINE/PubMed Citation on PubMed

[view all 65 results from MEDLINE/PubMed](#)
[similar results](#)

- ☐ 12. Ritonavir and saquinavir combination therapy for the treatment of HIV infection.

D W Cameron / A J Japour / Y Xu / A Hsu / J Mellors / C Farthing / C Cohen / (...) / **E Sun**, *AIDS*, Feb 1999

OBJECTIVE: To evaluate the safety and antiretroviral activity of ritonavir (Norvir) and saquinavir (Invirase) **combination therapy** in patients with HIV infection. DESIGN: A multicenter, randomized, open-label clinical trial. SETTING: Seven HIV...

MEDLINE/PubMed Citation on PubMed

[view all 65 results from MEDLINE/PubMed](#)
[similar results](#)

- ☐ 13. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency...

Nancy Shulman / Andrew Zolopa / Diane Havlir / Ann Hsu / Cheryl Renz / Sheila Boller / Ping Jiang / (...) / **Eugene Sun**, *Antimicrob Agents Chemother*, Dec 2002

...before the switch and 3 weeks after the switch. **Combination therapy** increased the indinavir predose concentrations...concentration in plasma achieved with indinavir-ritonavir **combination therapy**, was the best predictor of a viral load reduction...

MEDLINE/PubMed Citation on

PubMed

[view all 65 results from MEDLINE/PubMed](#)

[similar results](#)

- ☐ 14. [Crixivan, Norvir combination therapy studied.](#)

W Strain, *Posit Living*, Apr 1999

Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Ritonavir

MEDLINE/PubMed Citation on PubMed

[view all 65 results from MEDLINE/PubMed](#)

[similar results](#)

- ☐ 15. [Application for Inclusion of indinavir/low dose ritonavir on WHO Model List of E](#) [Word-113K] May 2002

...to IDV in full doses. It is less clear whether **combination therapy** is associated with less toxicity than full dose...Fund, it aims to have 7,000 patients on triple **combination therapy** by the end of 2007. At the end of 2001, an estimated...

[<http://www.who.int/medicines/organization/par/edl/indi...>]

[similar results](#)

- ☐ 16. [Norvir - Special Populations](#) [14K]

Oct 2002

...are no controlled or adequate studies of Norvir **combination therapy** taken by pregnant women. Norvir should only be...by breastmilk. The safety and benefits of Norvir **combination therapy** has been determined in children between the ages...

[more hits from](http://www.hivandhepatitis.com/hiv_and_aids/norvir_pop...) [http://www.hivandhepatitis.com/hiv_and_aids/norvir_pop...]

[similar results](#)

- ☐ 17. [\[Experiences with antiretroviral combination therapy\]](#)

U S Justesen / L H Mygind / S S Pedersen / C Pedersen, *Ugeskr Laeger*, Mar 1999

The purpose of the study was to evaluate the efficacy of treating of HIV infected patients with two nucleoside analogues and one protease inhibitor in clinical practice. Sixty-one patients were included and followed with respect to plasma HIV-RNA, CD4...

MEDLINE/PubMed Citation on PubMed

[view all 65 results from MEDLINE/PubMed](#)

[similar results](#)

- ☐ 18. [High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.](#)

V Jubault / M Burgard / E Le Corfec / D Costagliola / C Rouzioux / J P Viard, *AIDS*, Dec 1998

Adult; Anti-HIV Agents; CD4 Lymphocyte Count; DNA, Viral; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Leukocytes, Mononuclear; Male; Middle Aged; RNA, Viral; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load

MEDLINE/PubMed Citation on PubMed

[view all 65 results from MEDLINE/PubMed](#)

[similar results](#)

- ☐ 19. [Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial.](#)

O Kirk / T L Katzenstein / J Gerstoft / L Mathiesen / H Nielsen / C Pedersen / J D Lundgren, *AIDS*, Jan 1999

OBJECTIVES: To compare the efficacy and safety of indinavir 800 mg three times a day, ritonavir 600 mg twice a day, and a combination of ritonavir 400 mg twice a day and

saquinavir 400 mg twice a day, when administered with two nucleoside analogues....

MEDLINE/PubMed Citation on PubMed

[view all 65 results from MEDLINE/PubMed](#)
[similar results](#)

- ☐ **20.** [Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients...](#)

M Grodesky / E P Acosta / N Fujita / S Mason / J G Gerber, *HIV Clin Trials*, May 2001

PURPOSE: Ritonavir (RTV) and delavirdine (DLV) are inhibitors of cytochrome P450 (CYP) 3A4, the specific CYP that metabolizes indinavir (IDV). We hypothesized that patients who have failed multiple therapies containing protease inhibitors would still...

MEDLINE/PubMed Citation on PubMed

[view all 65 results from MEDLINE/PubMed](#)
[similar results](#)



Results Pages: [[<< Prev](#)] [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [[Next >>](#)]

[back to top](#)

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by [FAST](#) © Elsevier 2006


[About Us](#)
[Newsroom](#)
[Advisory Board](#)
[Submit Web Site](#)
[Help](#)
[Contact Us](#)
[Basic Search](#)
[Advanced Search](#) [Search Preferences](#)

☒ Journal sources ☒ Preferred Web sources ☒ Other Web sources ☐ Exact phrase

Searched for:: :All of the words:keyword:ritonavir AND ("combination therapy" AND metabolism)

 Found:: :64 total | [19 journal results](#) | [4 preferred web results](#) | [41 other web results](#)

 Sort by:: :relevance | [date](#)

- ☐ 1. [AEGIS-05CROI: Ritonavir \(RIT\) pharmacokinetics \(PK\) during combination therapy with delavirdine \(DLV\).](#) [6K]
 Feb 1998
 ...February 1-5, 1998 Ritonavir (RIT) pharmacokinetics (PK) during **combination therapy** with delavirdine (DLV). Conf Retroviruses Opportunistic...approximately 70%, presumably though inhibition of RIT oxidative **metabolism**. These data provide a rationale for a lower dose of RIT...
[more hits from \[http://www.aegis.com/conferences/CROI/1998/343.html\]](#)
[similar results](#)
- ☐ 2. [COMBINATION THERAPY FOR THE TREATMENT OF AIDS](#)
VACCA, Joseph, P. / LIN, Jiunn, H. / YEH, Kuang, C. / CHODAKEWITZ, Jeffrey, A. / DEUTSCH, Paul, J. / JU, William, D. / MERCK & / CO., INC., EUROPEAN PATENT, Oct 2000
 ...invention provides **combination therapy** for the treatment...invention to provide a **combination therapy** which lowers HIV...Lamivudine. This **combination therapy** is a method to enhance...due to extensive **metabolism** by CYP11A4 prior...
Full text available at patent office. For more in-depth searching go to  LexisNexis
[view all 4 results from Patent Offices](#)
[similar results](#)
- ☐ 3. [Pharmacy Key, May 1996](#) [11K]
 Jun 1998
 ...zidovudine and zalcitabine as triple **combination therapy** does not effect the absorption, **metabolism** or elimination of any of these drugs...zalcitabine or zidovudine as part of **combination therapy** are 0.75 mg TID and 200 mg TID, respectively...
[\[http://www2.kumc.edu/druginfo/pharmkey/PharmKeyMay96.h...\]](#)
[similar results](#)
- ☐ 4. [Application for Inclusion of indinavir/low dose ritonavir on WHO Model List of E](#) [Word-113K]
 May 2002
 ...activity, but because it inhibits the **metabolism** of indinavir. This is sometimes known...full doses. It is less clear whether **combination therapy** is associated with less toxicity than...aims to have 7,000 patients on triple **combination therapy** by the end of 2007. At the end of...

 Re
US
fo
an
do:
do:
dr
hiv
hiv
hiv
hu
vir
me
ne
nu
opi
pla
prc
Or
Al
F
Key
The
terr
Aw
Toc
Tak
new

[<http://www.who.int/medicines/organization/par/edl/indi...>]
[similar results](#)

- ☐ 5. [In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease...](#)
Nobuhito Shibata / Weihua Gao / Hiroyuki Okamoto / Tomoyuki Kishida / Yukako Yoshikawa / Kanji Takada, *J Pharm Pharmacol*, Feb 2002
...was 0.67, indicating that amprenavir **metabolism** in rat liver microsomes was strongly...other interaction processes besides **metabolism** in the liver. However, these results...of AIDS patients when they receive a **combination therapy** with two kinds of HIV protease inhibitor...


MEDLINE/PubMed Citation on PubMed

[view all 5 results from MEDLINE/PubMed](#)
[similar results](#)


- ☐ 6. [Table I](#) [PDF-370K]
Mar 2002
It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is available on the HIV/AIDS Treatment Information Service website (<http://www.hivatis.org>).
[more hits from](#) [http://stophiv.pitt.edu/news_events/pdfs/Feb4_2002_01....]
[similar results](#)
- ☐ 7. [RR5107-Front Cover.p65](#) [PDF-305K]
May 2002
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR 2002;51 (No. RR- 7):[inclusive page numbers].
[<http://www.cdc.gov/MMWR/PDF/rr/rr5107.pdf>]
[similar results](#)
- ☐ 8. [JOURNAL 7/02/YES](#) [PDF-144K]
Dec 2002
...Syndr 200229:340-345. **Combination therapy** with indinavir, ritonavir...the CYP3A4-mediated **metabolism** of protease inhibitors...inducer of delavirdine **metabolism**: A steady state pharmacokinetic...induction of its own **metabolism**. Efavirenz has an...continued PI-based **combination therapy** or were switched from...
[more hits from](#) [<http://www.hawaii.edu/hivandaids/ARV%20Drug%20Monograp...>]
[similar results](#)
- ☐ 9. [No Title](#) [PDF-92K]
Aug 2002
...ritonavir inhibits the CYP3A-mediated **metabolism** of lopinavir, thereby providing increased...metabolized by CYP3A. Ritonavir inhibits the **metabolism** of lopinavir, thereby increasing the...volunteers and HIV-positive patients. **Metabolism**: In vitro experiments with human hepatic...
[more hits from](#) [<http://www.fda.gov/cder/foi/label/2002/21251se8004lbl....>]
[similar results](#)
- ☐ 10. [D.99July_NL_12pg.QRK](#) [PDF-73K]
Sep 1999
...The Hopkins HIV Report July 1999 **Combination therapy** for HIV infection can reduce viral...in patients who are doing well on **combination therapy**. This mechanism involves the establishment...these cells, even in patients on **combination therapy** who have no detectable plasma virus...
[http://hopkins-aids.edu/publications/report/nl_99_july...]
[similar results](#)

11. [032901 Interactions among Drugs for HIV and Opportunistic](#) [PDF-77K]

- ☐ Mar 2002
...absorption, transport, distribution, **metabolism**, or excretion of a drug. In therapy...They may involve alterations in drug **metabolism** mediated by the cytochrome P-450 sys...and each of these drugs may alter the **metabolism** of other antiretroviral and concomitantly...
[more hits from \[http://www.ecu.edu/intmedresidency/currentresidents/Re...\]](#)
[similar results](#)

- ☐ 12. [Drug interactions/P450](#)
Shapiro, L.E. / Shear, N.H., *Current Problems in Dermatology*, May 2001
...villi and can account for first-pass **metabolism** of many drugs. These heme-containing...An increased understanding of drug **metabolism** is solving much of the mystery behind...3A4. When a drug is administered, its **metabolism** via a cytochrome may result in another...
Published journal article available from 
[view all 14 results from ScienceDirect](#)
[similar results](#)

- ☐ 13. [PIP23draft-final](#) [PDF-157K]
Feb 2001
...well. If this is your experience, the message is clear: as long as you're following the general "rules" about 3-drug **combination therapy**, just keep doing what you're doing. If you're one of the lucky few who at least temporarily achieve "undetectable" viral...
[\[http://www.projinf.org/pdf/pip23.pdf\]](http://www.projinf.org/pdf/pip23.pdf)
[similar results](#)

- ☐ 14. [In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: a possible...](#)
Mukhopadhyay, A. / Wei, B. / Zullo, S.J. / Wood, L.V. / Weiner, H., *Mitochondrion*, Oct 2002
...involved in the regulation of lipid **metabolism** (Carr et al., 1998a,b). Since lipodystrophy...the introduction of PIs as part of **combination therapy** for HIV infection, it was initially...mitochondrial function such as respiration or **metabolism**, although preliminary experiments in...
Published journal article available from 
[view all 14 results from ScienceDirect](#)
[similar results](#)

- ☐ 15. [Evolutionary Analysis of HIV - 1 Protease Inhibitors :](#) [PDF-48K]
Sep 2002
Evolutionary Analysis of HIV-1 Protease Inhibitors: Methods for Design of Inhibitors That Evade Resistance Daniel Stoffler, Michel F. Sanner, Garrett M. Morris, Arthur J. Olson, and David S.
[\[http://www.scripps.edu/~stoffler/publ/PDF/Coev2002.pdf\]](http://www.scripps.edu/~stoffler/publ/PDF/Coev2002.pdf)
[similar results](#)

- ☐ 16. [2002-A5.PDF](#) [PDF-182K]
Oct 2002
Copyright Aid for AIDS (Pty) Ltd 2002 No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or by any information storage or retrieval system without prior permission in writing from the Aid for AIDS programme.
[\[http://www.weforum.org/pdf/Initiatives/GHI_HIV_DCSA_Ap...\]](http://www.weforum.org/pdf/Initiatives/GHI_HIV_DCSA_Ap...)
[similar results](#)

- ☐ 17. [Simultaneous determination of indinavir, ritonavir and lopinavir \(ABT 378\) in human plasma by high-performance liquid...](#)
Ray, J. / Pang, E. / Carey, D., *Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences*, Aug 2002
...inhibits the cytochrome3A-mediated **metabolism** of LOP leading to an increase in

plasma...Potentials coadministered drugs used in **combination therapy** with INV, RTV and LOP, including HIV-reverse...variability in drug absorption, distribution, **metabolism** and excretion. Drug dose is a poor...

Published journal article available from  **SCIENCE @ DIRECT**

[view all 14 results from ScienceDirect](#)
[similar results](#)

- ☐ **18. [Antiretroviral drug toxicity - a challenge for the hepatologist?](#)**
Spengler, U. / Lichterfeld, M. / Rockstroh, J.K., *Journal of Hepatology*, Feb 2002
...liver, particularly when fatty acid **metabolism** is also blocked due to the mitochondrial...it soon became evident that NRTI **combination therapy** carries a considerable risk of causing...agent in patients on antiretroviral **combination therapy** [35,36] . Didanosine seems to be particularly...

Published journal article available from  **SCIENCE @ DIRECT**

[view all 14 results from ScienceDirect](#)
[similar results](#)

- ☐ **19. [JOURNAL 7/02](#)** [PDF-263K]
Aug 2002
Zuniga SR VICE PRESIDENT/COS Michael S. Glass CONTROLLER Harry J. Snyder
INTERNATIONAL ASSOCIATION OF PHYSICIANS IN AIDS CARE Southern Africa Regional
Office Johannesburg, South Africa INTERIM EXECUTIVE DIRECTOR Mulamba Diese
DEPUTY DIRECTOR TBA IAPAC MONTHLY EDITOR-IN-CHIEF José M.
[http://www.thebody.org/iapac/pdfs/jul02.pdf]
[similar results](#)

- ☐ **20. [Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease...](#)**
N Shibata / Y Matsumura / H Okamoto / Y Kawaguchi / A Ohtani / Y Yoshikawa / K Takada, *J Pharm Pharmacol*, Oct 2000
...in-vitro data, suggesting the presence of other interaction processes besides **metabolism** in the liver. These results provide useful information for the treatment of AIDS patients receiving **combination therapy** with two HIV-1 protease inhibitors.

MEDLINE/PubMed Citation on  **PubMed**

[view all 5 results from MEDLINE/PubMed](#)
[similar results](#)

 **fast**

Results Pages: [[<< Prev](#)] [1](#) [2](#) [3](#) [4](#) [[Next >>](#)]

[back to top](#)

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by [FAST](#) © Elsevier 2006

SCIRUS

[About Us](#)
[Newsroom](#)
[Advisory Board](#)
[Submit Web Site](#)
[Help](#)
[Contact Us](#)
[Basic Search](#)
[Advanced Search](#)
[Search Preferences](#)

☒ Journal sources
 ☒ Preferred Web sources
 ☒ Other Web sources
 ☐ Exact phrase

Searched for:: :All of the words:keyword:ritonavir AND ("combination therapy" AND metabolism AND gr

 Found:: :16 total | [4 journal results](#) | 0 preferred web results | [12 other web results](#)

 Sort by:: :relevance | [date](#)

☐ 1. [Drug interactions/P450](#)

Shapiro, L.E. / Shear, N.H., *Current Problems in Dermatology*, May 2001
 ...ketoconazole inhibits cyclosporine **metabolism**), chemicals (dioxin is an inducer of CYP3A4, and a food such as **grapefruit** juice is an inhibitor of CYP3A4 **metabolism**), and the environment (cigarette...propensity to cause arrhythmias. **Grapefruit** juice caused QT prolongation in patients...Astemizole (Hismanal) undergoes extensive **metabolism** to active metabolites, and, as is...

Published journal article available from [SCIENCE @ DIRECT](#)

[view all 4 results from ScienceDirect](#)

[similar results](#)

☐ 2. [Update: Clinically Significant Cytochrome P-450 Drug Interactions \[PDF-131K\]](#)
 Mar 2001

...inhibition and induction, microsomal drug **metabolism** is affected by genetic polymorphisms...cause arrhythmias.9 Fresh or frozen **grapefruit** juice inhibits CYP3A4 enzymes found...effects.5254 Inhibition of terfenadine **metabolism** with quantifiable levels of the terfenadine...were reported in patients ingesting **grapefruit** juice 240 ml concomitantly with terfenadine...
 [http://otc.isu.edu/~hurley/cyp450.pdf]

[similar results](#)

☐ 3. [032901 Interactions among Drugs for HIV and Opportunistic \[PDF-77K\]](#)
 Mar 2002

...CYP3A4 may alter intestinal or hepatic **metabolism** of other drugs. The 20-fold increase...inhibition of CYP3A4 at both sites. 20 **Grapefruit** juice contains various substances that inhibit CYP3A4-mediated **metabolism** only in the wall of the gut, mainly...ing concomitant administration of **grapefruit** juice. 11 However, **grapefruit** juice...

[http://www.ecu.edu/intmedresidency/currentresidents/Re...]

[similar results](#)

☐ 4. [Table I \[PDF-370K\]](#)

Mar 2002

It is emphasized that concepts relevant to HIV management evolve rapidly.

Refine your search using these key words found in the results:
[antiretroviral agents](#)
[antiretroviral therapy](#)
[drug interactions](#)
[grapefruit juice](#)
[hiv-infected patients](#)
[inhibitors](#)
[nelfinavir](#)
[plasma hiv rna level](#)
[viral load](#)
[zidovudine](#)

Or refine using:

The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is available on the HIV/AIDS Treatment Information Service website (<http://www.hivatis.org>).

[more hits](#)

[from \[http://stophiv.pitt.edu/news_events/pdfs/Feb4_2002_01....\]](http://stophiv.pitt.edu/news_events/pdfs/Feb4_2002_01....)

[similar results](#)

5. [Conference Highlights \(various\) -- BETA:1/98 - AEGIS \[192K\]](#)

Jan 2000

BETA January 1998. Important note: Information in this article was accurate in January 1998. The state of the art may have changed since the publication date.

[more hits from \[http://www.aegis.com/pubs/beta/1998/be980110.htm\]](http://www.aegis.com/pubs/beta/1998/be980110.htm)

[similar results](#)

6. [RR5107-Front Cover.p65 \[PDF-305K\]](#)

May 2002

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR 2002;51(No. RR- 7):[inclusive page numbers]. [<http://www.cdc.gov/MMWR/PDF/rr/rr5107.pdf>]

[similar results](#)

7. [JOURNAL 7/02/YES \[PDF-144K\]](#)

Dec 2002

...Syndr 200229:340-345. **Combination therapy** with indinavir, ritonavir...in liquid (avoid **grapefruit** juice) taking the...CYP3A4- mediated **metabolism** of protease inhibitors...inducer of delavirdine **metabolism**: A steady state pharmacokinetic...induction of its own **metabolism**. Efavirenz has an...continued PI-based **combination therapy** or were switched... [<http://www.hawaii.edu/hivandaids/ARV%20Drug%20Monograp...>]

[similar results](#)

8. [2002-A5.PDF \[PDF-182K\]](#)

Oct 2002

Copyright Aid for AIDS (Pty) Ltd 2002 No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or by any information storage or retrieval system without prior permission in writing from the Aid for AIDS programme.

[http://www.weforum.org/pdf/Initiatives/GHI_HIV_DCSA_Ap...]

[similar results](#)

9. [JOURNAL 7/02 \[PDF-263K\]](#)

Aug 2002

Zuniga SR VICE PRESIDENT/COS Michael S. Glass CONTROLLER Harry J. Snyder INTERNATIONAL ASSOCIATION OF PHYSICIANS IN AIDS CARE Southern Africa Regional Office Johannesburg, South Africa INTERIM EXECUTIVE DIRECTOR Mulamba Diese DEPUTY DIRECTOR TBA IAPAC MONTHLY EDITOR-IN-CHIEF José M.

[<http://www.thebody.org/iapac/pdfs/jul02.pdf>]

[similar results](#)

10. [The protease inhibitors](#)



Tapp Alter, K., Primary Care Update for OB/GYNS, Mar 2001

...replication process, **combination therapy** provides for...first-pass hepatic **metabolism**. Food also...erythromycin, and **grapefruit** juice. If...part of a **combination therapy**. The elimination...when used in **combination therapy**. 3 Adverse...

Published journal article available from **SCIENCE @ DIRECT**

[view all 4 results from ScienceDirect](#)

[similar results](#)

- ☐ **11. Therapeutic drug monitoring of antiretroviral agents** [PDF-29K]
Jul 2000
...fasting state. A glass of reconstituted **grapefruit** juice in- creases plasma saquinavir...concentration by 50%, and double-strength **grapefruit** juice increases plasma con- centrations...are eliminated by either hepatic **metabolism**, renal excre- tion, or both. Hepatic...c .1 7 Patients were treated with **combination therapy** consisting of two NRTIs and one PI...
[\[http://www.iscpubs.com/articles/acl/c0005bea20.pdf\]](http://www.iscpubs.com/articles/acl/c0005bea20.pdf)
[similar results](#)
- ☐ **12. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents**
The Case Manager, Sep 1997
...bioavailability Serum half-life Route of **metabolism** Storage Adverse effects Drug interactions...capsule: 4%, erratic 1-2 hours Biliary **metabolism** p450 cytochrome 3A4 Room temperature...increased by ritonavir, ketoconazole, **grapefruit** juice Â Saquinavir levels reduced...alkaloids 20-80% 3.5-5 hours Biliary **metabolism** p450 cytochrome 3A4 Room temperature...
Published journal article available from  **SCIENCE @ DIRECT**
[view all 4 results from ScienceDirect](#)
[similar results](#)
- ☐ **13. Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus**
Lewis, J.S. / Terriff, C.M. / Coulston, D.R. / Garrison, M.W., *Clinical Therapeutics*, Mar 1997
...agents as monotherapy versus use in **combination therapy** with other antiretroviral medications...cell counts and viral loads.12 **Combination Therapy** Significant reductions in viral...monotherapy, zalcitabine monotherapy, and **combination therapy** using the two agents. Saquinavir...
Published journal article available from  **SCIENCE @ DIRECT**
[view all 4 results from ScienceDirect](#)
[similar results](#)
- ☐ **14. toc** [PDF-305K]
Feb 2001
February 5, 2001 Guidelines for the Use of Antiretroviral Agents in HIV- Infected Adults and Adolescents Table of Contents Guidelines Panel Roster..... i
Summary.....
[\[http://stophiv.pitt.edu/news_events/pdfs/Feb5_2001.pdf\]](http://stophiv.pitt.edu/news_events/pdfs/Feb5_2001.pdf)
[similar results](#)
- ☐ **15. The 1592 Controversy -- BETA:6/97 - AEGIS** [34K]
Apr 1998
...saquinavir HGC in **combination therapy** is more effective...medications or with **grapefruit** juice will...when used in **combination therapy**, can achieve...attained with **combination therapy** including...medications or with **grapefruit** juice will...
[\[http://www.aegis.com/pubs/beta/1997/BE970601.htm\]](http://www.aegis.com/pubs/beta/1997/BE970601.htm)
[similar results](#)
- ☐ **16. Conference Highlights (various) -- BETA:1/98 - AEGIS** [192K]
Jan 2000
BETA January 1998. Important note: Information in this article was

accurate in January 1998. The state of the art may have changed since the publication date.

[<http://www.aegis.com/pubs/beta/1998/BE980110.htm>]

[similar results](#)



[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by FAST © Elsevier 2006

About Us

Newsroom

Advisory Board

Submit Web Site

Help

Contact Us

Basic Search

[Advanced Search](#) [Search Preferences](#)

keyword:ritonavir AND (450 AND "combination therapy"

Search

☒ Journal sources
 ☒ Preferred Web sources
 ☒ Other Web sources
 ☐ Exact phrase

Searched for:: :All of the words:keyword:ritonavir AND (450 AND "combination therapy" AND metabolism

Found:: :10 total | [1 journal results](#) | [0 preferred web results](#) | [9 other web results](#)Sort by:: :relevance | [date](#)[Save checked results](#)[Email checked results](#)[Export checked results](#)

- ☐
- 1.
- [Update: Clinically Significant Cytochrome P-450 Drug Interactions](#)
- [PDF-131K]
-
- Mar 2001

...concerning the cytochrome P-450 isoenzymes and increased...induction, microsomal drug **metabolism** is affected by genetic...extensive first-pass **metabolism** to active metabolites...have 86 CYTOCHROME P-450 DRUG INTERACTIONS Michalets...Inhibition of terfenadine **metabolism** with quantifiable levels...in patients ingesting **grapefruit** juice 240 ml concomitantly...

[http://otc.isu.edu/~hurley/cyp450.pdf]

[similar results](#)

Refine your search using these keywords found in the results:

[nelfinavir](#)[protease](#)[saquinavir](#)[viral load](#)[zidovudine](#)

Or refine using:

[All of the words](#)

- ☐
- 2.
- [032901 Interactions among Drugs for HIV and Opportunistic](#)
- [PDF-77K]
-
- Mar 2002

...advance unknown Altered drug **metabolism** Induction of cytochrome P-450 Rifabutin and saquinavir...Inhibition of cytochrome P-450 (hepatic and gastrointestinal...Inhibition of cytochrome P-450 (gastrointestinal only) **Grapefruit** juice and saquinavir 11...

[http://www.ecu.edu/intmedresidency/currentresidents/Re...]

[similar results](#)[Refine](#)

- ☐
- 3.
- [Drug interactions/P450](#)

Shapiro, L.E. / Shear, N.H., Current Problems in Dermatology, May 2001

...ketoconazole inhibits cyclosporine **metabolism**), chemicals (dioxin is an inducer of CYP3A4, and a food such as **grapefruit** juice is an inhibitor of CYP3A4 **metabolism**), and the environment (cigarette...propensity to cause arrhythmias. **Grapefruit** juice caused QT prolongation in patients...Astemizole (Hismanal) undergoes extensive **metabolism** to active metabolites, and, as is...

Published journal article available from [SCIENCE @ DIRECT](#)[similar results](#)

- ☐
- 4.
- [Conference Highlights \(various\) -- BETA:1/98 - AEGIS](#)
- [192K]

Jan 2000

BETA January 1998. Important note: Information in this article was accurate in January 1998. The state of the art may have changed since the

publication date.

more hits from [<http://www.aegis.com/pubs/beta/1998/be980110.htm>]

similar results

5. Table I [PDF-370K]

Mar 2002

It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is available on the HIV/AIDS Treatment Information Service website (<http://www.hivatis.org>).

more hits

from [http://stophiv.pitt.edu/news_events/pdfs/Feb4_2002_01....]

similar results

6. JOURNAL 7/02/YES [PDF-144K]

Dec 2002

...Syndr 200229:340-345. **Combination therapy** with indinavir, ritonavir...in liquid (avoid **grapefruit** juice) taking the...CYP3A4- mediated **metabolism** of protease inhibitors...inducer of delavirdine **metabolism**: A steady state pharmacokinetic...induction of its own **metabolism**. Efavirenz has an...continued PI-based **combination therapy** or were switched...

[<http://www.hawaii.edu/hivandaids/ARV%20Drug%20Monograp...>]

similar results

7. RR5107-Front Cover.p65 [PDF-305K]

May 2002

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR 2002;51(No. RR- 7):[inclusive page numbers].

[<http://www.cdc.gov/MMWR/PDF/rr/rr5107.pdf>]

similar results

8. JOURNAL 7/02 [PDF-263K]

Aug 2002

Zuniga SR VICE PRESIDENT/COS Michael S. Glass CONTROLLER Harry J. Snyder INTERNATIONAL ASSOCIATION OF PHYSICIANS IN AIDS CARE Southern Africa Regional Office Johannesburg, South Africa INTERIM EXECUTIVE DIRECTOR Mulamba Diese DEPUTY DIRECTOR TBA IAPAC MONTHLY EDITOR-IN-CHIEF José M.

[<http://www.thebody.org/iapac/pdfs/jul02.pdf>]

similar results

9. Conference Highlights (various) -- BETA:1/98 - AEGIS [192K]

Jan 2000

BETA January 1998. Important note: Information in this article was accurate in January 1998. The state of the art may have changed since the publication date.

[<http://www.aegis.com/pubs/beta/1998/BE980110.htm>]

similar results

10. toc [PDF-305K]

Feb 2001

February 5, 2001 Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents Table of Contents Guidelines Panel Roster..... i

Summary.....

[http://stophiv.pitt.edu/news_events/pdfs/Feb5_2001.pdf]

similar results

fast

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by [FAST](#) © Elsevier 2006